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  ABSTRACT 
The ins and outs of stem cells: regulation of cell fate in embryonic stem cells and 
hematopoiesis 
Melanie Diane Mumau 
 
The decisions stem cells make impact both the development of adult vertebrates and 
systems within the body that require cellular replenishment to sustain life. Regardless whether a 
stem cell remains quiescent, divides, differentiates, or undergoes apoptosis—these processes 
are precisely controlled by internal gene regulatory networks that are instructed by external 
stimuli. The exact mechanisms governing stem cell fate are not completely understood.  
These studies explore new ways in which cell fate is mediated. Through a study of 
mitochondrial content in human embryonic stem cells (hESCs) and their differentiated progeny, 
we discovered differences in mitochondrial morphologies. Mitochondria began as elongated and 
networked structures in self-renewing conditions and changed their shape after differentiation. 
The addition of external growth factors that direct hESCs toward the definitive endoderm (DE) 
lineage promoted mitochondrial fragmentation, which was mediated by the mitochondrial fission 
machinery. Globular, punctate mitochondria were observed prior to the induction of the DE-
specific transcriptional program. Differentiation of hESCs to other lineages did not result in any 
mitochondrial shape changes. Thus, mitochondrial fission in differentiating hESCs, an internal 
cellular process, is induced by DE-inducing external stimuli, an effect that was lineage specific.   
 In a second study, we investigated the role of the splenic environment in the 
development of the blood system—during hematopoiesis. The spleen made a distinct 
contribution to hematopoiesis, a process predominantly attributed to the bone marrow. We 
discovered a previously unidentified population of cells, uniquely represented in the mouse 
spleen that could develop into erythrocytes, monocytes, granulocytes, and platelets. These 
multipotent progenitors of the spleen (MPPS) expressed higher levels of the transcription factor, 
	  NR4A1 compared to their bone marrow counterparts and relied on NR4A1 expression to direct 
their cell fate. The activation of NR4A1 in MPPS biased their production of monocytes and 
granulocytes in vitro whereas NR4A1-deficient MPPS over-produced erythroid lineage cells in 
vivo. Together, these data suggest the splenic niche supports distinct myeloid differentiation 
programs of multi-lineage progenitors cells.         
 Both studies identify new mechanisms by which external stimuli regulate internal 
mechanisms of cell fate. These insights provide a better understanding of stem and progenitor 
cell differentiation that have the potential to impact cellular replacement therapies.    
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Cell fate—the determination of the future state of a living cell is paramount to cell 
biology. Whether it’s the development of an organism, cellular replacement after injury or in 
response to infection, the choices cells make impact what they will become. At any given time a 
cell has four choices: it can divide, differentiate, die, or do nothing. Through cell division, a cell 
doubles, generating an exact replica or an entirely different cell. Examples of cells that actively 
proliferate in adult vertebrates include skin, gut, and immune cells. In addition, cancer 
represents a disease of active, aberrant proliferation [1]. Cellular differentiation is the ability of a 
cell to change or become something different. In the development of the immune system for 
example, undefined cells differentiate into more specified cell types that function to fight 
infection [2]. Critical to the developing organism, cell death or apoptosis produces shapes of the 
body, carving out the initial round ball of cells of the embryo and creating the spacing between 
human fingers and toes [3]. Finally, by remaining the same through quiescence, blood stem 
cells persist in the body for extended periods of time and are only called to action in response to 
stress [4]. Quiescent cells avoid unnecessary cell divisions that could potentially lead to cancer. 
These cellular tasks are exquisitely regulated both intrinsically from within and extrinsically by 
external factors. In naturally occurring environments, most cell types undergo only one or two of 
these processes in their lifetime. Stem cells, alternatively, can perform them all and therefore 
represent an attractive candidate to study cell fate decisions.  
Through the development of techniques that allow for the study of stem cells in both their 
naturally occurring environment and artificial laboratory conditions, the knowledge of stem cell 
fate choices has expanded rapidly in the past 25 years. The ability to grow stem cells outside of 
the human body contributed to a significant understanding of human development, genetic 
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disease, and basic principles of how cells are wired [5, 6]. In addition, the study of stem cells in 
mouse and zebrafish model systems helped significantly improve therapies, particularly in 
cancer [7]. The therapeutic gains from stem cell research are not only extensive, but they 
continue to grow. Stem cell research promises to inform cancer treatments even further and has 
the potential to generate cellular replacements to treat a wide range of diseases [8, 9].     
 
1.2. Introduction to stem cells  
       
Stem cells are defined by two functional characteristics: the ability to self-renew and the 
ability to differentiate. Stem cells self-renew or proliferate while maintaining their potential. By 
differentiating, stem cells develop into more specified cell types. The number of cell types a 
stem cell can become determines its potency. If a stem cell has the potential to generate all 
cells of an organism, such as embryonic stem cells, that cell is “pluripotent”. More specialized 
stem cells, like adult stem cells that produce multiple cell types of one specific organ, are 
“multipotent”. For example, gut stem cells develop into all cells of the intestinal epithelium [10]. 
Restricted cell types that only have the capacity to generate one or two more specified cell 
types are called uni-potent or bi-potent progenitors.     
Pluripotent stem cells (PSCs) include embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs). Embryonic stem cells exist for a short period of time in nature, 
but can be isolated from both human and mouse embryos and grown in culture for extended 
periods of time [5, 11, 12]. Somatic cells with essentially no potential can be induced to a 
pluripotent state through the ectopic expression of transcription factors Oct4, Sox2, Klf4, and 
cMyc [13]. These induced PSCs and ESCs generate all three germ layers that form all tissues 
of the adult organism. Adult stem cells are more specified and are maintained in the adult 
organism throughout life. Although not defined in every organ, adult stem cells have been 
identified in the bone marrow, brain, lung, skin, and gut [14].  
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1.3. Pluripotent Stem Cells  
 
1.3.1 Two pluripotent states of embryonic stem cells 
 
Two types of embryonic stem cells termed naïve and primed ESCs reflect distinct 
developmental stages that retain both self-renewing capacity and differentiation potential. They 
express a core transcriptional network Oct4, Sox2, and Nanog, but differ with respect to 
epigenetic status, morphology, and expression of pluripotent-associated regulatory transcription 
factors [15]. Mouse ESCs, derived from pre-implantation embryos when grown in the presence 
of leukemia inhibitory factor (LIF) display dome-shaped, compact colonies. These naïve ESCs 
maintain two active X chromosomes and express the transcription factors Stella, Rex1, and high 
levels of Klf4. Primed ESCs, derived from both pre- and post-implantation embryos, have only 
one active X chromosome and respond to bFGF and ActivinA to maintain pluripotency. These 
are better known as epiblast stem cells (EpiSCs) in the mouse and are most similar to cultured 
hPSCs that phenotypically grow as more flat-shaped colonies. Functionally, compared to primed 
ESCs, naïve ESCs more efficiently contribute to chimeras and the germline when injected into 
morula stage blastocysts. Recently, several groups have defined cell culture conditions to 
generate and maintain naïve pluripotency in human ESCs in the absence of induced transgenes 
[16-18].  The establishment of human naïve pluripotency defines a new stage to study human 
development and has potential implications for regenerative medicine. Naïve PSCs clonally 
expand more effectively than conventional hPSCs; therefore, naïve PSCs are better equipped 






1.3.2. Maintenance of pluripotent stem cells through external signals   
 
Pluripotent stem cells maintained in defined culture systems rapidly expand while 
preserving their full potential to generate all tissues of an adult organism [19]. In a developing 
embryo, embryonic stem cells divide for a finite period of time and differentiate in order to 
properly develop into a fully functioning organism. PSCs that rapidly grow in culture while 
remaining undifferentiated represent an artificial state. Some culture conditions support 
continuous PSC proliferation and maintenance while others support differentiation suggesting 
that extrinsic signals must regulate ESC developmental programs.  
The maintenance of PSCs in vitro requires soluble growth factors that are added to 
culture medium. In addition, PSCs are often grown on mitotically inactivated fibroblasts that 
secrete growth factors and provide a more suitable surface for PSCs to attach instead of 
standard plastics [5, 20]. In the absence of these factors that promote self-renewal, PSCs will 
undergo precocious differentiation. In their most naïve form, PSCs require LIF [21], a cytokine 
belonging to the IL-6 family that signals through its membrane bound receptor [22]. LIF activates 
the stem cell core regulatory machinery Oct4, Sox2, and Nanog while simultaneously inhibiting 
differentiation programs (Figure 1.1) [23]. Receptor bound LIF recruits the membrane protein 
gp130 stimulating multiple signaling pathways [24]. The LIF/LIFR/gp130 complex signals 
through JAK to promote STAT3 translocation to the nucleus and activation of Sox2 [23, 25]. 
Activation of the JAK/STAT3 pathway also helps suppress the endoderm and mesoderm 
transcriptional programs [26]. In addition to STAT3, LIF dependent JAK also signals through the 
PI3K/AKT pathway [27]. JAK phosphorylation of PI3K leads to AKT activation, which 
phosphorylates GSK3β relieving it of its interaction with β-catenin [28]. β-catenin enters the 
nucleus, transcribes TCF3, which regulates Oct4, Sox2, and Nanog in self-renewing PSCs [29]. 
Since β-catenin also signals through canonical Wnts, these data suggest a role for Wnt-
signaling in the maintenance of PSCs. Indeed, the addition of the Wnt-agonist CHIR99021 to 
	  5 
PSC culture medium helps prevent PSCs from differentiating [30]. Thus, external factors 





Figure 1.1. External regulation of self-renewal and differentiation programs by LIF. LIF 
mediates PSC self-renewal by promoting the activation of the pluripotency transcriptional 
network while repressing lineage specific programs. Figure adapted from [31] and [23]. 
 
 
 Three transcription factors—Oct4, Sox2 and Nanog, comprise the core regulatory 
machinery required for maintaining pluripotency in both mouse and human ESCs (Figure 1.1) 
[32]. Their role in early development was first described in mouse knockout studies. Early stage 
mouse cells deficient for Oct4, Sox2, or Nanog fail to generate embryonic stem cells and 
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therefore do not develop past the embryonic stage [33-35]. Studies of ESCs in culture also 
illustrate their importance for ESC self-renewal. Knocking down any of these transcription 
factors in culture leads to differentiation [36-38]. Over-expression of Nanog promotes ESC self-
renewal in the absence of LIF, bypassing STAT3 [39]. Enhanced Oct4 expression, however, 
results in ESC differentiation, thereby suggesting that Oct4 expression is tightly regulated in 
pluripotent ESCs [36]. Promoter binding analyses suggest Oct4, Sox2, and Nanog bind to their 
own promoters and to each other’s, indicating the ESC self-renewal machinery is self-regulated 
[32].  
Many factors influence the core pluripotent transcriptional network including other 
transcription factors, co-factors, and epigenetic modulators. Transcription factors, like Stat3, 
Klf4, Smad1, Foxo1, Sall4, Esrrb, and Tbx3, bind directly to the promoter regions of Oc4, Sox2, 
and Nanog and regulate their transcription [40-43]. Some of these same transcription factors 
along with other co-factors form complexes with the members of the core machinery to influence 
their activity through protein-protein interactions [44-46]. Epigenetic regulation of pluripotency, 
including DNA methylation, histone modifications, and chromatin structure, adds an additional 
layer of control that helps maintain stem cells in their undifferentiated state [47].            
Pluripotent stem cell differentiation, which mimics development, follows Waddington’s 
proposed epigenetic landscape: undifferentiated cells with the most potential become 
progressively more restricted through a set of guidelines that directs their developmental fate 
[48]. In naturally occurring environments, development proceeds in a hierarchical and step-wise 
manner mediated by transcriptional and epigenetic mechanisms such that once a particular 
program is initiated, the fate of a cell is unlikely to change course. Differentiation to a specific, 
mature cell type is guided by precise DNA methylation patterns and nucleosome 
rearrangements that allow for the transcriptional activation of lineage specific genes and 
repression of other cell-type specific genes and the pluripotency network [49]. Although 
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precisely governed by cell intrinsic mechanisms, externally driven signaling pathways instruct 
cell fate specification [40].  
The discovery of iPSCs challenged Waddington’s model of development and suggested 
that re-activation of the pluripotency network is sufficient to alter cell fate. Published by Nobel 
laureate Dr. Shinya Yamanaka, differentiated dermal fibroblasts transduced with a specific set 
of transcription factors are transformed to embryonic-like stem cells with pluripotent potential 
[50]. These studies demonstrate that, although normal development is tightly regulated and 
involves both internal and external factors, cell fate mechanisms are more plastic than originally 
proposed.   
 
1.3.3. Differentiation by defined factors  
 
 The generation of iPSCs led other groups to hypothesize that if cells can be 
reprogrammed to a pluripotent state, they can also undergo trans-differentiation to another cell 
type with a different function. For example, mature fibroblasts can be directly converted to 
neurons or hepatocytes [51, 52]. These techniques offer one way of generating specific cell 
types for their use in cellular replacement therapies. However, a much more common approach 
to generating cell sources for regenerative medicine follows normal developmental paradigms 
and employs induction of lineage specification through defined factors added directly to PSC 
cultures—called directed differentiation. Directed differentiation attempts to generate functional, 
mature cell types from PSCs by mimicking development [6]. This is achieved through activation 
of specific transcriptional programs mediated by external cues.  
Differentiating embryonic stem cells first generate the three germ layers—endoderm, 
mesoderm, and ectoderm through a process called gastrulation (Figure 1.2A) [53]. Definitive 
endoderm (DE) produces cells in the upper respiratory tract, including the lung and trachea, 
liver, pancreas, and gut [54]. The blood system, muscle, bone, kidney, and heart develop from 
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the mesoderm. The ectoderm layer forms the central nervous system and epidermal layer of the 
skin. During gastrulation, ESCs undergo an epithelial to mesenchymal transition (EMT), egress 
through an area called the primitive streak, and exit as mesoderm or DE [53, 55]. Ectoderm is 
the only germ layer that does not enter the primitive streak. As the cells proliferate and migrate, 
they pass through signaling centers at distinct regions of the embryo (Figure 1.2B) [56]. Where 
and when the cells pass through these signaling centers define their cell fate. For example, cells 
destined to become DE traverse the primitive streak last, exiting near a region called the node 
[57]. Adjacent to the node, these cells are exposed to high levels of the morphogen Nodal, 









Figure 1.2. PSC differentiation follows 
development paradigms. (A) In the embryo, 
ESCs generate the three germ layers: 
endoderm, mesoderm, and ectoderm through 
a process known as gastrulation. (B) A 
representation of the developing mouse 
embryo at gastrulation. During gastrulation, 
the original ball-shape of the embryo is 
hollowed out and forms a cup-like structure. 
Cells that will become endoderm (yellow) exit 
the region of the primitive streak and are 
defined by high Nodal signaling and 
progressively migrate toward a region with 
Nodal inhibitory signals (Lefty). Figure adapted 
from [56].     	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DE induction in mouse and human PSC cultures can be obtained by adding high levels 
of ActivinA to media [61], mimicking high levels of Nodal secreted at the node. Identified by 
CXCR4+/cKit+/EpCAM+ cell surface expression, DE can be achieved at relatively high purities 
[62]. These cells are then further specified by distinct sets of growth factors to produce lung, 
liver, pancreas, and intestinal cells [63-68]. Directed differentiation techniques have also been 
defined for differentiating mesoderm and ectoderm lineages [69-75].     
  The field of directed differentiation has produced many relevant cell types including 
cardiomyocytes, neurons, hepatocytes, and airway epithelial cells [63, 76-78]. For each cell 
type, the addition and removal of growth factors and cytokines initiates a transcriptional program 
that governs cell fate specification towards a particular lineage. Once the proper transcriptional 
program is initiated, downstream targets will be appropriately regulated and result in the cell 
type of interest. Elegant work has shown the influence of genetic and epigenetic factors that 
affect cell fate specification [79-81]. Thus, cellular differentiation is determined by sophisticated 
gene regulatory networks yet induced by external cues.   
 
1.4. Mitochondria and pluripotent stem cells  
 
1.4.1. Functions of mitochondria  
 
Even though directed differentiation of PSCs has produced many cell types [82], both 
efficiency of lineage commitment as well as functionality of the end-stage cell type remain major 
challenges in the field, revealing gaps in our understanding. A more thorough characterization of 
the cell biology of hPSCs and their derivatives will likely improve directed differentiation 
techniques. One area of research in hPSC biology that is not well understood is the role of 
mitochondria. 
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 Mitochondria are dynamic organelles that change in total content and shape depending 
on cell-type specific requirements. Mitochondria undergo biogenesis, fusion and fission events, 
and mitophagy to meet those requirements. Mitochondria maintain their own genome consisting 
of 37 genes that encode 13 proteins important for the respiratory chain, 22 tRNAs, and 2 rRNAs 
[83]. Other mitochondrial proteins are nuclear encoded. Mutations in mtDNA, both inherited and 
arising de novo, affect a variety of organs having the most pronounced effects on cells with 
high-energy demand, such as neurons and cardiomyocytes [84].  
Mitochondria are best known for their role in energy metabolism. Cellular respiration 
couples glycolysis to the citric acid cycle and the electron transport chain. Glycolysis, the 
process by which glucose is converted into pyruvate, occurs in the cytosol and yields 2 
molecules of ATP per molecule of glucose. In low oxygen environments, pyruvate is further 
metabolized to lactate and is thereafter secreted by the cell. In oxygen rich environments, 
pyruvate is oxidized to acetyl-CoA in the mitochondrial matrix and enters the citric acid cycle. 
Further oxidation of citric acid cycle products yields another 34 to 36 molecules of ATP. The role 
of mitochondria extends beyond cellular respiration and includes steroid biosynthesis, fatty acid 
metabolism, apoptosis, Ca2+ homeostasis, innate immunity, and signaling [85-89].   
 
1.4.2. Mitochondria in development  
 
Mitochondria and mitochondrial DNA (mtDNA) are maternally inherited. Mitochondria 
present in the oocyte rapidly decline in number with each cell division. As cells divide and 
mitochondrial segregation ensues, mitochondria and mtDNA are diluted since mitochondrial 
biogenesis does not begin until implantation [90]. This has important implications for both 
energy production and mtDNA segregation in the early embryo [91].   
Although mitochondria in the oocyte are immature with underdeveloped cristae, they are 
abundant in number and function as the main source of energy production through preferential 
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metabolism of pyruvate over glucose, a characteristic that is maintained in the one-cell embryo 
post-fertilization of the oocyte [90]. As development ensues and the number of mitochondria per 
cell decreases with each cell division, there is a concurrent rise in expression of the glucose 
transporter, GLUT3 [92]. These events—the reduction in mitochondrial content and increase in 
glucose transport may explain why there is a shift in energy production from aerobic metabolism 
through oxidative phosphorylation (OXPHOS) in the earliest stages of development to anaerobic 
metabolism through glycolysis at implantation when the supply of oxygen is limited within the 
uterine wall (Figure 1.3) [93]. After implantation, as development proceeds and the embryo 
becomes vascularized, there is a shift back to OXPHOS as the main source of ATP generation. 
Embryonic stem cells from both mouse and human embryo sources are derived peri-
implantation and share similar metabolic profiles to the developing embryo, as discussed in 
detail further below.   
 
 
Figure 1.3. Mitochondrial content changes coincide with energy production in the 
developing embryo. The embryo originally generates energy from oxidative phosphorylation in 
mitochondria provided by the oocyte. Because mitochondrial biogenesis does begin until the 
time of implantation around E4.5, dilution of mitochondrial content ensues. During this time, 
energy production shifts from oxidative phosphorylation to glycolysis until the embryo begins to 
generate new mitochondria. ESCs are derived from peri-implantation embryos. Figure adapted 
from [94].     
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Mitochondrial segregation in the early embryo and blastocyst plays an important role in 
preventing the accumulation of mutant mtDNA [91]. Segregation of mitochondrial DNA products 
through cell division generates cells in the early embryo with varying ratios of normal to mutant 
mtDNA, termed heteroplasmy. Although maternal mtDNA typically contains some degree of 
heteroplasmy, individual cells in the early embryo with mutant mtDNA can eliminate 
degenerated mitochondria, albeit through unknown mechanisms. This protects the developing 
fetus from inheriting mutant mtDNA products, which can have profound effects on mitochondrial 
respiratory function. Although it takes roughly 60% of mutant mtDNA content within a cell to 
affect its function [95], mtDNA mutations have deleterious effects in tissues that have high 
respiratory requirements. There are two mechanisms to eliminate damaged mitochondria in the 
developing embryo: 1) mitophagy which is a mitochondrial specific form of autophagy to recycle 
or remove mitochondrial contents, and 2) selective elimination of cells with low respiratory 
function through apoptosis.  
 
1.4.3. Mitochondrial dynamics 
 
The processes of fusion and fission, termed mitochondrial dynamics, are critical for 
mitochondrial integrity and function. Mitochondrial dynamics affect many biological processes 
including metabolism, autophagy, apoptosis, cell division, and the development of different 
tissue types [96]. Fused mitochondria are important for transmission of mitochondrial membrane 
potential, mixing of mitochondrial DNA gene products, and escaping autophagy during 
starvation [97-102]. Several key players in mitochondrial fusion have been described. The 
mitofusin genes, Mfn1 and Mfn2, encode large transmembrane GTPases that fuse the outer 
mitochondrial membrane (Figure 1.4A) [96, 103]. The GTPase activity of MFN1 exceeds that of 
MFN2 [104], although both are partially redundant with respect to fusion [103]. Residing on the 
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inner mitochondrial membrane, optic atrophy protein 1 (Opa1) induces inner membrane fusion 





Figure 1.4. Components of the mitochondrial dynamics machinery. (A) OPA1 and MFN1/2 
mediate mitochondrial fusion. (B) Mitochondrial fission proteins included the recruitment factor 
FIS1 and fission effector molecule, DRP1. Figure adapted from [107].    
 
 
Mitochondrial fission can be a response to cell division, apoptosis, mitochondrial 
dysfunction followed by mitophagy, and transport by the cytoskeleton to facilitate mitochondrial 
distribution [108-111]. Mitochondrial fission during mitosis is thought to contribute to a stochastic 
distribution of mitochondria among daughter cells [109, 112]. The main GTPase involved in 
fission, dynamin-related protein (Drp1) facilitates fission of mitochondrial organelles upon its 
recruitment to the mitochondrial membrane (Figure 1.4B) [113]. Deletion of Drp1 in mice 
promotes mitochondrial elongation in mouse embryonic fibroblasts and embryonic stem cells 
[114].  
  DRP1 is post-translationally regulated by phosphorylation, SUMOlaytion, ubiquitination, 
and S-nitrosylation [96]. DRP1 contains two phosphorylation sites at serine 637 and serine 616, 
which are inhibitory and activating marks, respectively [109, 115]. In steady state, DRP1 is 
dispersed throughout the cytosol [113]. During mitochondrial fission, DRP1 is recruited to 
mitochondria where it forms oligomers at the mitochondrial scission site [108, 116, 117]. Several 
proteins are known to be involved in DRP1 recruitment, including FIS1, MFF (Mitochondrial 
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Fission Factor), and MiD49 and MiD51 (Figure 1.4) [118-121]. In addition, DRP1 recruitment to 
the mitochondria during mitosis is facilitated by RALA, activated by AuroraA phosphorylation 
and RALBP1 [122].  
 
1.4.4. Mitochondrial dynamics in development  
 
Knockout studies provide evidence for a role of fusion and fission factors in 
development. Mice lacking Mfn1, Mfn2, Opa1 or Drp1 die in utero, and evidence suggests that 
they die during organ development rather than in the earlier stages of gastrulation [103, 114, 
123, 124]. Conditional deletion of Drp1 impairs neural development by inducing apoptosis [114]. 
Cardiac specific ablation of Mfn1 and Mfn2 results in fragmented mitochondria in cardiomyocyte 
progenitors and severely inhibited cardiomyocyte development in vivo [125]. From these data, it 
can be inferred that mitochondrial dynamics are dispensable for early gestation, but fusion and 
fission proteins play essential roles in the development of specific tissues in mice. However, the 
role of mitochondrial dynamics in early human development remains unknown. Further 
investigation of mitochondrial dynamics in human PSCs might define new mechanisms of 
maintenance and differentiation that could impact stem cell biology and regenerative medicine.  
 
1.4.5. Mitochondria in pluripotent stem cells  
 
Studies on the role of mitochondria in hPSCs has primarily focused on their role in 
energy metabolism [126]. Mouse PSCs, reflecting a pre-implantation state, are energetically 
bivalent, generating ATP from both glycolysis and OXPHOS [127]. Consistent with 
developmental studies, mouse EpiSCs and human ESCs favor glycolysis to generate ATP, 
perhaps as an adaptation to low oxygen availability in the post-implantation embryo [90]. hPSCs 
contain functional respiratory complexes, but rely primarily on glycolysis [127, 128]. In addition 
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to up-regulating glycolysis-associated genes [129], evidence suggests hPSCs uncouple 
respiration at multiple stages. Compared to fibroblasts, hPSCs contain higher levels of pyruvate 
dehydrogenase kinase 1 (PDHK1) and its target, phosphorylated PDH, which in its un-
phosphorylated state catalyzes the conversion of pyruvate to acetyl-CoA [129]. Human PSCs 
also express uncoupling protein 2 (UCP2) that was shown to promote glycolysis and inhibit 
reactive oxygen species (ROS) production [128]. UCP2 expression decreases dramatically and 
acutely with differentiation. Although less efficient than OXPHOS, glycolysis is a way for the cell 
to quickly produce energy without generating ROS that could be potentially harmful to the cell. 
Similar to cancer cells, PSCs rapidly proliferate and must balance energy production with 
biosynthetic demands. It is possible that, similar to cancer cells, PSCs turn to glycolysis to 
generate energy while utilizing the pentose phosphate pathway for nucleotide and lipid 
biosynthesis. 
 
1.5. Hematopoietic stem cells 
 
1.5.1. The hematopoiesis hierarchy 
 
The long-term hematopoietic stem cell (LT-HSC) generates all cell types of the blood, 
including red blood cells, white blood cells, and platelets that are constantly replenished 
throughout the lifetime of an adult organism; a process called hematopoiesis (Figure 1.5). 
Starting with the LT-HSC, hematopoiesis proceeds sequentially through a series of progenitor 
and precursor cells that ultimately produce all mature blood lineages. Through new studies and 
evolving technologies, the exact hematopoietic hierarchy is constantly being re-evaluated and is 





    
Figure 1.5. Model of hematopoiesis. The hematopoietic stem cell sits at the apex of the 
hierarchy and generates multiple mature cells in the blood with diverse functions by first 
differentiating into multipotent and committed progenitor populations with more restricted 
potential. Figure adapted from [130].     
 
 
Hematopoietic stem cells (HSCs) maintain a multipotent state in vivo throughout the 
lifetime of adult vertebrates. The factors that influence HSCs self-renewal are not completely 
defined and, therefore, HSCs are unable to be preserved in culture for an extended period of 
time. In addition to elucidating the mechanisms of HSC maintenance, the ability to rapidly 
expand HSCs ex vivo has tremendous therapeutic applications [131]. Bone marrow stem cell 
transplants, coupled with gene editing techniques, could be used to treat various blood 
disorders, cancer, and immunodeficiency [132-134]. The potential benefits of expanding and 
manipulating HSCs outside of the body and in the laboratory has led to the discovery of 
	  17 
components of the stem cell niche, although the exact signals and conditions required to 
maintain HSCs remain incomplete.    
 
1.5.2. External regulation of hematopoietic stem cells—the bone marrow niche 
 
Hematopoietic stem cells reside in the bone marrow of adult vertebrates, although they 
can also be found in the peripheral blood, spleen, and liver. In the past two decades, mouse 
models have helped define components within the bone marrow niche that are important for 
stem cell maintenance, illustrating that the environment regulates stem cell fate. Cellular 
ablation techniques indicated specific stromal cell types within the bone marrow required for the 
retention and stability of HSCs. These populations include osteoblasts, Nestin+ and Leptin 
receptor positive (LEPR+) mesenchymal cells, non-myelinating Schwann cells, CAR cells, 
megakaryocytes, and macrophages (Figure 1.6) [135-143]. In all of these studies, the loss of 




Figure 1.6. The bone marrow niche. The niche provides multiple cell types that provide a 
nurturing environment that maintains HSCs in the bone marrow. Figure adapted from [144]. 
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Although many cell types occupy the HSC niche and have been shown to be critical for 
HSC maintenance, exactly how these cells regulate HSCs is not well defined. Some signals that 
promote HSC maintenance have been identified, including CXC-motif chemokine ligand 12 
(CXCL12), stem cell factor (SCF), thrombopoietin, and TGFβ [145-151]. These growth factors 
are expressed by neighboring cells and bind to cognate receptors on HSCs representing non-
cell autonomous, or extrinsic regulation of HSCs. Conditional deletion of SCF and CXCL12 
within endothelial cells and LEPR+ stromal cells resulted in depletion of HSCs from the bone 
marrow [152, 153]. These studies reveal that perivascular cells secrete factors required for HSC 
maintenance, supporting the niche where HSCs reside.   
Sophisticated imaging techniques confirm that HSCs localize within the perivascular 
niche next to arterioles and sinusoids [154, 155]. Despite their proximity to the vasculature, 
HSCs reside in a hypoxic environment as determined by in vivo measurements of oxygen 
concentrations directly in the bone marrow (Figure 1.6) [156]. These data confirm early studies 
suggesting that many types of stem cells, including HSCs, prefer a low oxygen environment. 
Low oxygen tension causes HSCs to express hypoxia-inducible factor 1a (HIF1α), which 
functions to prevent HSCs from entering the cell cycle and to remain in a quiescent state [157]. 
Together, these studies indicate that external, molecular forces also exert influence over HSCs.    
 
 
1.5.3. Other regulators of hematopoietic maintenance 
 
Advancements in bone marrow transplantation or hematopoietic cell transplantation 
(HCT) provide additional examples of external signals that affect stem cell maintenance. 
Granulocyte colony stimulating factor, or G-CSF, a cytokine that induces neutrophil 
differentiation [158-160], was first used to treat neutropenia in cancer patients [161, 162]. Later, 
G-CSF was shown to mobilize hematopoietic cells, including stem cells, from the bone marrow 
into circulation improving hematopoietic cell collection techniques [163, 164]. Even though this 
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discovery was made almost 30 years ago, the exact mechanism of G-CSF mobilization of bone 
marrow stem cells into the periphery remains unclear. Mature hematopoietic cells, but not 
hematopoietic stem and progenitor cells, require expression of G-CSF receptor for mobilization 
[165]. These studies suggest G-CSF influences hematopoietic stem and progenitor cells 
indirectly, possibly by interfering with the CXCL12 interaction with its receptor, CXCR4, allowing 
detachment of HSCs from the niche [166].   
Another more recently discovered molecule that is currently in clinical trials has the 
potential to also improve HCT [167]. HSCs treated with prostaglandin E2 (PGE2) or its more 
stable derivative, 16,16-dimethyl-PGE2, show enhanced engraftment [168]. An immunologically 
relevant lipid shown to have both immunosuppressive and stimulatory effects [169], PGE2 binds 
to HSCs through its receptor and improves HSC survival, homing, and proliferation after 
transplantation [170]. Interestingly, only one hour of PGE2 stimulation generates significant 
improvements of HSC function after transplant, indicating PGE2 treatment affects HSCs potently 
and immediately. Thus, HSCs are especially sensitive to externally delivered stimulants, 
including PGE2. 
 
1.5.4. Intrinsic mechanisms of hematopoietic stem cell fate  
 
 Although HSC maintenance requires a tightly controlled environment, the extent to which 
external signals influence HSC differentiation remains up for debate. Recent work provides 
evidence that LT-HSCs are lineage primed, indicating that their differentiation is pre-determined 
rather than influenced by external factors. Even though the discovery of specific cell surface 
markers has helped identify and isolate LT-HSCs at high purities [171, 172], single-cell analysis 
has revealed heterogeneity among LT-HSCs [173]. After transplantation, single LT-HSCs that 
were phenotypically similar generated different outputs; some LT-HSCs favored either myeloid 
or lymphoid lineage commitment while others were more balanced [174, 175]. These data 
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suggest that the range of cell types into which an individual LT-HSC can differentiate may be 
fixed, i.e. is cell intrinsic.  
Additional studies support the idea that LT-HSC fate is pre-determined, following 
stochastic differentiation programs. High expression of CD150, a cell surface marker that 
identifies LT-HSCs, biases LT-HSCs towards myeloid lineage commitment whereas CD150low 
LT-HSCs generate a more balanced lymphoid to myeloid output [176, 177]. Similarly, 
expression of von Willebrand factor (vWF) in LT-HSCs specifies their lineage commitment 
towards platelets [178]. Thus, expression of certain proteins within the LT-HSC compartment 
biases their cell fate. Furthermore, a recent study published by Yu et al. tracked individual LT-
HSCs using fluorescent tags and discovered that individual LT-HSCs generated from the same 
clone displayed similar differentiation patterns during homeostasis and regeneration [179]. 
Therefore, the development of LT-HSCs into mature cell types is largely fixed, or cell intrinsic.  
 
 
1.5.5. External signals instruct hematopoietic progenitor populations 
 
Although LT-HSC development into mature cells occurs stochastically rather than being 
instructed, other hematopoietic progenitors follow inductive signals. Multipotent progenitors or 
MPPs, like LT-HSCs, have the capacity to develop into all mature hematopoietic cells, but have 
limited self-renewing capabilities [172]. Even though LT-HSCs have the potential to generate all 
blood cell types under transplantable conditions after irradiation, it is becoming more evident 
that these more restricted MPPs populate blood cells under steady state conditions [180, 181]. 
Similar to LT-HSCs, MPPs lack the expression of mature lineage markers, express Sca1 and 
cKit+ (LSK), and are further distinguished by Flt3, CD48 and CD150 expression (Figure 1.7A). 
Different populations of MPPs, phenotypically and functionally distinct, predominantly 
differentiate towards monocyte/granulocyte lineages, erythrocyte/megakaryocyte cells, or 
lymphocytes during homeostasis (Figure 1.7B) [182, 183]. However, during regeneration 
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following myeloablation, MPP sub-populations alter their usual developmental fate and 
preferentially produce myeloid cells first, before re-populating lymphoid cells. Unlike LT-HSCs 
whose fates are pre-determined, MPP populations change their fate depending on the 
environmental context. Thus, certain populations of hematopoietic progenitors are externally 






Figure 1.7. Identification of HSPC sub-populations and their lineage bias. (A) Bone marrow 
and splenic Lin-Sca1+cKit+ cells were first examined for FLT3 expression. FLT3-positive 
expression identifies MPP4 and FLT3-negative cells were subsequently profiled for CD150 and 
CD48 expression identifying MPP2, MPP3, ST-HSCs, and LT-HSCs as indicated. (B) A 





 Few studies identify factors that control hematopoietic progenitor differentiation. 
Macrophage colony stimulating factor (M-CSF) activates the PU.1 myeloid transcriptional 
program within the LSK compartment [184], most of which are MPPs [183]. The addition of G-
CSF or M-CSF to bi-potent granulocyte-macrophage progenitors (GMPs) stimulates their 
differentiation towards granulocytes or monocytes, respectively. These studies demonstrate that 
extrinsic growth factors instruct bi-potent and multipotent populations of hematopoietic 
progenitors. 
 External factors regulate cell fate by helping to maintain HSCs, the hematopoietic cell 
with the most potential, and by stimulating specific differentiation patterns in more restricted 
progenitor cells. The identification of other factors that control cell fate will improve our 
understanding of the basic mechanisms that regulate hematopoietic stem and progenitor cells 
thus informing future stem cell therapies and will also provide insight into how blood cancers 
modulate normal hematopoiesis.  
 
1.5.6. NR4A1, an externally regulated transcription factor  
 
External signals that influence cell fate instruct cells by activation of a specific 
transcriptional program. The identification of transcription factors sensitive to environmental 
stimuli will provide mechanistic insight to how external factors exert their control. The orphan 
nuclear receptor, NR4A1 or Nur77 represents one candidate transcription factor for studying 
extrinsic mechanisms of cell fate.   
NR4A1 belongs to a family of three structurally related transcription factors, which 
appear to regulate transcription as soon as they are translated, i.e. without ligand activation. 
As an immediate early response gene, induction of NR4A1 expression occurs in as little as 15-
90 minutes [185]. Diverse stimuli are known to stimulate NR4A1 expression that include G-
protein coupled receptor agonists such as PGE2, growth factors like TGFβ, and inflammatory 
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cytokines [186-190]. Once translated, NR4A1 modulates transcription in various ways. NR4A1 
itself activates transcription by binding directly to the NGFI-B response element (NBRE) or Nur-
response elements (NurREs) in the promoter regions of its targets’ genes [191, 192]. Although 
NR4A1 can bind to DNA as a monomer, it often acts in concert with other proteins [193]. Both 
co-activators and co-repressors interact directly with NR4A1, thereby activating or suppressing 
its transcriptional activity. Indirectly, NR4A1 also associates with other transcription factors and 
affects their activity. Thus, through its wide range of activation, regulation, and influence on 
other proteins, NR4A1 likely impacts diverse cellular processes.  
 
 
Figure 1.8. Diverse stimuli activate NR4A1 expression that impact cell fate.  
 
The physiological consequences of NR4A1 actions include cell fate choices such as 
proliferation, differentiation, and apoptosis (Figure 1.8). In cancer cells for example, the 
interaction between NR4A1 and β-catenin leads to ubiquitination and subsequent complex 
degradation, thus inhibiting cancer cell proliferation [194]. NR4A1 also forms a complex with 
fibroblast growth factor receptor 1 (FGFR1) and retinoid X receptor-α (RXRα) in the nucleus of 
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differentiating pluripotent stem cells [195]. In addition to its various protein-protein interactions, 
the compartmentalization of NR4A1 affects its function as well. During negative selection of T 
cells in the thymus, T-cell receptor (TCR)-stimulated immature thymocytes up-regulate NR4A1, 
which remains in the nucleus and induces transcription of pro-apoptotic genes resulting in cell 
death [196, 197]. In mature T cells, however, NR4A1 induced by TCR-activation leads to its 
accumulation on mitochondria [196]. These studies illustrate NR4A1 affects varied, distinct 
cellular processes through its interactions with other molecules.  
 In addition to its role in lymphocyte development, NR4A1 also affects myeloid cell 
differentiation at distinct stages of hematopoiesis. Expression of NR4A1 is required for terminal 
monocyte differentiation: Nr4a1-null mice lack non-inflammatory, patrolling monocytes and have 
reduced numbers of their precursors— classical, inflammatory monocytes [198, 199]. NR4A1 
also influences cell fate within the hematopoietic stem and progenitor cell compartment. NR4A1 
expression within the LT-HSC population identifies myeloid-biased cells [187]; however, 
whether it functions to direct their lineage choice remains uncertain. Along with other family 
members, NR4A1 helps prevent malignant transformation in myeloid progenitor cells [200, 201], 
suggesting that NR4A1 functions within HSPCs, but not by itself. Thus, an independent role for 
NR4A1 in myeloid cell development has not yet been discovered.     
 The studies in this thesis investigate externally induced regulation of cell fate in two 
models of differentiation. First, we employ directed differentiation techniques to explore whether 
mitochondria impact differentiation of PSCs. With the addition of soluble growth factors to PSC 
cultures, we induce differentiation to different lineage cell types and determine the role of 
mitochondria during the activation of lineage specification programs. In a second study, we 
investigate how NR4A1 regulates myeloid progenitor differentiation and the extent to which the 
environment influences its control. Both studies attempt to expand the knowledge of cell fate in 
cells with differentiation potential with the hope of advancing the field of stem cell research.   
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Chapter 2 – Mitochondrial dynamics in embryonic stem cells and their derivatives 
 



























 Human pluripotent stem cells (hPSCs) maintain the capacity to develop into all cells in 
the adult. hPSCs can be differentiated into specific, mature cell types using defined factors 
through a process called directed differentiation. Directed differentiation techniques model 
developmental paradigms that stipulate external signals guide cell fate specification by 
activating precise transcriptional programs [6]. Prior knowledge of vertebrate development from 
predominantly mouse models allowed for rapid advancements of generating relevant cell types 
using these methods. In recent years, many cell types have been differentiated from hPSCs 
including cardiomyocytes, intestinal epithelial cells, hepatocytes, neurons, and lung airway cells 
[63, 64, 68, 72, 73]. Even through continual advancements, directed differentiation techniques 
struggle to generate cells with clinically relevant applications. A better understanding of cell fate 
specification, particularly in human models, will help produce functional cell types for cell 
replacement therapies. To better understand hPSCs and their immediate progeny, we 
investigated the functional role of mitochondria among differentiating hPSCs. hPSCs displayed 
elongated, tubular mitochondria that fragment upon differentiation to definitive endoderm (DE), 
the germ layer that produces cells of the upper respiratory tract, gut, and endocrine organs [54]. 
No changes in mitochondrial shape were detected in hPSCs differentiated to neuroectoderm 
(NE) and mesoderm (MD), the other germ layers that together with DE comprise the vertebrate 
embryo. The DE-specific mitochondrial fragmentation was accompanied by changes in Drp1 
regulation and localization to the mitochondria, indications of active mitochondrial fission. 
Importantly, the DE-induced mitochondrial fragmentation occurred prior to activation of the DE-
specific transcriptional program. Together, these data suggest germ-layer specific activation of 
the mitochondrial fission pathway that potentially drives cell fate specification in hPSCs.       
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2.2. Introduction  
 
Mitochondria serve the cell in ways that extend beyond energy metabolism and play a 
role in steroid biosynthesis, Ca2+ homeostasis, apoptosis, autophagy and innate immunity [85-
89]. Morphological changes of mitochondria alter the mitochondria’s diverse functions resulting 
in a variety of consequences within the cell. Mitochondria change shape in response to certain 
stimuli that either directly or indirectly induce the release of second messengers [88]. 
Mitochondrial outputs include ATP, ROS, Ca2+, and metabolic intermediates like NADH and 
alpha-ketoglutarate, all of which affect a wide range of processes and effector molecules in the 
cytoplasm and nucleus. As a signaling organelle, mitochondria have the potential to influence 
gene regulatory networks that control cell fate mechanisms. In this way, mitochondria could help 
drive stem cell maintenance and differentiation. Mitochondrial morphology may also reflect 
functions that are cell type specific. Since mitochondria change shape to meet metabolic and 
other physiological demands, it is likely that mitochondria among different developing cell types 
change in shape to meet those requirements.   
The discovery of factors that facilitate mitochondrial fusion and fission helped define a 
relationship between mitochondrial structure and function. Knocking out individual factors 
involved in mitochondrial dynamics in mice—Mfn1/2, Opa1, or Drp1 results in mitochondrial 
shape defects and embryonic lethality suggesting that changes in mitochondrial morphology 
result in physiological consequences [103, 114, 123, 124]. Mitochondrial fission effector Drp1 
promotes mitochondrial fragmentation that supports proper segregation of mitochondria during 
cell division and sensitizes cells to apoptosis and mitophagy. Fusion proteins facilitate 
mitochondrial elongation to generate a higher respiratory capacity, to buffer Ca2+, and to prevent 
apoptosis [96]. From these data, it appears that mitochondrial morphology, as controlled by 
mitochondrial dynamics, influences particular cell processes that inhibit normal embryonic 
development; however its role in early gestation and during the development of specific cell 
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types is less clear. Whether mitochondrial morphology promotes or reflects cell identity in stem 
cells and their early progenitors remains an important topic for investigation. 
Previous reports describe mitochondria in mouse pluripotent stem cells (PSCs) as 
globular, peri-nuclear in location, and present in low abundance [202]. These reports also show 
that during differentiation, mitochondria develop well-defined cristae and increase in overall 
biomass and reactive oxygen species (ROS) production. From these data, it was proposed that 
the phenotypic characteristics of mitochondria in mouse PSCs reflect their low respiratory 
capacity [202]. However, later studies indicate that mouse embryonic stem cells (mESCs) utilize 
both glycolysis and respiration to generate ATP [127]. Their distinct features led Lonergan et al. 
to propose that mitochondrial function, location, and morphology could potentially serve as a 
stem cell marker [203]. With the emergence of stem cells with varying degrees of pluripotent 
potential [16, 204], it is possible to determine if these characteristics are maintained in all 
pluripotent stem cells including human-derived PSCs (hPSCs). Whether mitochondrial 
morphology merely reflects specific stem cell states or plays a functional role in stem cell 
maintenance and differentiation remains unknown.  
A study of mitochondrial dynamics, known to facilitate mitochondrial morphological 
changes, in human pluripotent stem cells and their derivatives will provide insight into 
mitochondrial function in early development and its effects, if any, on early cell fate decisions.  
These findings may reveal a previously unknown connection between mitochondrial 








2.3. Experimental Procedures 
 
Cell culture 
hESCs: RUES2 (Rockefeller University Embryonic Stem Cell line 2) were cultured on mouse 
embryonic fibroblasts (MEFs) (Global Stem, Rockville, MD) plated at a density of 
~25,000cells/cm2. Cells were maintained in 5% CO2/air environment in media containing 
DMEM/F12 (Corning), 20% knockout serum replacement (Life Technologies), β-
mercaptoethanol (0.1mM, Sigma), 2mM Glutamax (Life Technologies), and 1% Pen/Step 
(Cellgro Corning) with 20ng/mL bFGF (R&D Systems). Medium was changed daily and cells 
were passaged every 3-4 days at a 1:24 dilution using Accutase/EDTA (Innovative Cell 
Technologies).         
 
mESCs: We obtained mouse ESC lines CCE and MM13 from the Mt. Sinai Stem Cell Core and 
from the laboratory of Hynek Wichterle (Columbia University), respectively. Mouse ESCs were 
cultured on MEFs and were maintained in ‘2i +LIF’ media containing Neurobasal media and 
DMEM/F12 (1:1, Life Technologies), N2 and B27 supplements (Life Technologies), 0.05% 
bovine serum albumin (BSA, Life Technologies), Pen/Strep, and Glutamax. This basal media 
was supplemented with monothioglycerol (MTG, 0.14µM, Sigma), CHIR99021 (3uM, Stemgent), 
PD0325901 (1µM, Stemgent), and leukemia inhibitory factor (LIF) (103U/mL, Millipore). Medium 
was changed daily and cells were passaged every 3-4 days at a 1:12 dilution using 
Accutase/EDTA. Cells were maintained in a 5%/air environment.  
 
mEpiSCs: The mouse EpiSCs were a gift generated from the laboratory of Michael Shen 
(Columbia University). Cultured mEpiSCs were maintained in similar conditions to hESCs with 
10ng/mL bFGF.                
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Definitive endoderm induction: DE generations was performed as previously described and as 
follows [205]. Depletion of MEFs was performed by dissociating and plating hESCs onto 
Matrigel-coated plates. Cells were then briefly trypsinized and plated in ultra-low attachment 
plates (Corning). Differentiations were performed at 5%O2/5%CO2 in serum-free differentiation 
media (SFD) containing IMDM/F12 (3:1), N2 and B27 supplements, 0.05% BSA, 50µg/mL 
ascorbic acid, 0.4µM MTG, Pen/Step, and Glutamax. After trypsinization, hESCs were placed in 
day 0 media containing SFD supplemented with Rock Inhibitor Y27632 (10µM, Tocris) and 
BMP4 (3ng/mL, R&D Systems) for 24 hours. Embryoid bodies (EBs) were collected at day 1 
and gently re-plated in media containing SFD supplemented with 10 µM Rock Inhibitor, 
0.05ng/mL BMP4, 2.5ng/mL bFGF, and 100ng/mL ActivinA (R&D Systems). At day 3 media 
was replaced with fresh ‘day 1’ media. At day 4 EBs were collected and tested for DE markers: 
PE conjugated CXCR4 (Invitrogen, MHCXCR404, 1:200), and APC conjugated c-KIT 
(Invitrogen, CD11705, 1:200) by flow cytomtery.  
 
For induction of DE from mESCs, MM13 cells were plated at a density of 100,000 cells/mL in 
sterile petri dishes in SFD media without supplements, similar to previous methods with slight 
modifications (ref. Valerie’s paper). After 2 days, EBs were collected, media removed and cells 
were dissociated to a single cell suspension and re-plated at 100,000 cells/mL in SFD 
supplemented with 100ng/mL ActivinA for 2 to 4 days.          
 
Mesoderm induction:  hESCs were differentiated as previously described in a 5%O2/5%CO2 
environment [206].  RUES2 cells were dissociated from renewing conditions on MEFs and 
plated directly into ultra-low attachment plates at a cell density of 2:3 in StemPro34 media (Life 
Technologies) with additives (50µg/mL ascorbic acid, 0.4µM MTG, Glutamax, and Pen/Strep) 
and supplemented with 10 µM Rock Inhibitor Y27632 and 3ng/mL BMP4. For 24 hours. At day 
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1, media was replaced with StemPro34 media with additives and 10ng/mL BMP4, 6ng/mL 
ActivinA, and 5ng/mL bFGF. After 3 days, media was removed and replace with StemPro34, 
additives, IWP2 (1µM, Tocris), and VEGF (10ng/mL, R&D Systems) for one day. Cells were 
then analyzed using flow cytometry with antibodies against KDR (R&D Systems, FAB357P, 
1:100) and PDGFRα (R&D Systems, FAB1264A, 1:100).           
  
Neuroectoderm induction hESCs were plated onto Matrigel-coated plates at a density of 
~60,000cells/cm2 in hESC media. After 24 hours or until nearly confluent, cells were washed in 
PBS and placed in SFD media supplemented with LDN193180 (100nM, Stemgent) and 
SB431542 (10µM, Tocris) as previously described [77]. Media was changed daily and after 7 
days cells were fixed (see below) and stained for PAX6 (Covance) and SOX2 (Stemgent) to 
determine differentiation efficiency.        
 
Imaging of mitochondria  
Cells were plated onto Matrigel-coated (diluted 1:30, Life Technologies) coverglass chamber 
slides.  Cells were stained with 50nM Mitotracker Red dye (Life Technologies) and Hoechst 
33342 (Life Technologies) for 30 minutes. For live cell imaging, cells were washed with PBS 
and immediately imaged using a fluorescent microscope (Leica DMI 4000B) fitted with a 100x 
objective.  
 
Quantification of mitochondrial length     
Individual mitochondria per field of view were traced in images obtained with a calibrated 
microscope using Image J.  To determine mitochondrial length and network, the ‘Shape 
Descriptors’ Image J plug-in was used to generate aspect ratio and form factor, from which 
area-weighted form factor was calculated.     
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Cell fixation   
Mouse ESCs could be fixed after staining with Mitotracker Red dye without any observed 
disruption to mitochondrial structure. After staining with Mitotracker Red dye, mESCs were fixed 
in 4% paraformaldehyde (PFA) for 10 minutes. This fixation method was also used for detection 
of nuclear antigens in hESCs.  Fixing mitochondria in hESCs proved problematic; 4% PFA 
fixation disrupted mitochondrial structure (see Figure 2.3). We did find that fixation with 4% PFA 
for 10 minutes, followed immediately by ice cold methanol for 1 minute preserved mitochondrial 
structure well.           
 
Immunofluorescence 
After fixation, cells were washed in PBS, permeabilized for 15 minutes in PBS containing normal 
donkey serum (5%, Millipore) 1% BSA and 0.2% Triton X-100 after which Triton X-100 was 
removed and the cells were the cells were blocked for another 45 minutes. Primary antibodies 
were incubated overnight at 4oC. Primary antibodies included: OCT4 (Santa Cruz, sc-5279, 
1:100), SOX2 (Stemgent, 09-0024, 1:200), FOXA2 (Santa Cruz, sc-6554, 1:100), PAX6 
(Covance, PRB-278P, 1:300), and DRP1 (DLP1, BD Transduction Laboratories, 611112). Cells 
were washed 3 times in PBS and incubated with secondary antibodies. Secondary antibodies 
were donkey anti-mouse whole IgG-Alexa Fluor 488 (715-545-150), donkey anti-mouse whole 
IgG-Alexa Fluor 647 (715-605-150), donkey anti-rabbit whole IgG-Alexa Fluor 488 (711-545-
152), donkey anti-rabbit whole IgG-Cy3 (711-166-152), donkey anti-rabbit whole IgG-Alexa 
Fluor 647 (711-605-152), donkey anti-goat whole IgG-Alexa Fluor 488 (705-545-003), donkey 
anti-goat whole IgG-Cy3 (705-165-147), donkey anti-goat whole IgG-Alexa Fluor 647, (705-605-





Co-localization analysis    
For each image, the nuclear area was removed from each channel due to high intensity staining 
from clustered mitochondria that may have confounded the results. Pearson’s correlation 
coefficient was generated using the co-localization Image J bundle.     
 
Quantitative PCR   
Total RNA was isolated from samples using Trizol (Invitrogen) and extracted using phase lock 
tubes (5 prime) and the RNeasy Kit (Qiagen) that included DNAse I treatment. Total RNA was 
reverse transcribed using Superscript III (Life Technologies) to generate cDNA. Real time 
quantitative PCR was performed on the ABI vii7A Thermocycler (Applied Biosystems (Life 
Technologies)) using ABI Power SYBR Green PCR Master Mix (Applied Biosystems (Life 
Technologies)). Each sample, using 5-10ng of cDNA, was analyzed in triplicate. The PCR 
conditions were 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s 
and 60 °C for 1 min; a melt curve was generated for each gene to ensure a single gene product 
was amplified. Absolute quantification was obtained using serially diluted genomic DNA 
standards and normalized to housekeeping gene β-ACTIN.  Primer sequences are listed in the 
table below.    
 
Gene Forward Primer (5’à3’) Reverse Primer  (5’à3’) 
ACTB TTTGAATGATGAGCCTTCGTGCCC GGTCTCAAGTCAGTGTACAGGTAAGC 
BRY CAGTGGCAGTCTCAGGTTAAGAAGGA CGCTACTGCAGGTGTGAGCAA 
FOXA2 TTCAACCACCCGTTCTCCATCAAC TGTTCGTAGGCCTTGAGGTCCATT 
GSC GCATGTTCAGCATCGACAACATCCT CGGGTAGAAGGCGCCATAGTC 
MEOX1 TGG TGG ACA CCA CAG GA CTT TCT CCG CCT GGA TGA TTT  
MESP1 GCCAGTGAGCGGGAGAAACT CCACGGACGGCGGTAGAAA 
MESP2  CTT CCA GCT CAG TGA AGC AA CTC CAG ATC TTC TTG CCA AAG T 
MIXL1 CTGTGCTCCTGGAACTGAAACGAA TGACCTTGGGAGCTAGAGTCAGAGATG 
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NANOG CCTGAAGACGTGTGAAGATGAG GCTGATTAGGCTCCAACCATAC 
NKX2.5 TGGAGAAGACAGAGGCGGACAA ATAGACCTGCGCCTGCGAGAA 
OCT4 AACCTGGAGTTTGTGCCAGGGTTT TGAACTTCACCTTCCCTCCAACCA 
PAX6 CTGCTGGCTGGCTTACTTCT ATTCCCACCTCTTGCACCTG 
SOX1 GAAGGAGCACCCGGATTAC CAGCGAGTACTTGTCCTTCTT 
SOX2 GCACATGAAGGAGCACCCGGATTA CGGGCAGCGTGTACTTATCCTTCTT 
SOX17 TTCGTGTGCAAGCCTGAGAT GGACACCACCGAGGAAATGG 
TBX3 CCCGGTTCCACATTGTAAGAG GTATGCAGTCACAGCGATGAAT 
TBP TGAGTTGCTCATACCGTGCTGCTA CCCTCAAACCAACTTGTCAACAGC 
 
For other genes, we used the comparative Ct method. RNA was isolated and cDNA was 
generated as before, however, RT-qPCR was performed using TaqMan Universal Master Mix II, 
no UNG (Life Technologies), and the following 20X TaqMan probes: 




mouse Mfn2 Mm00500133_m1 
DRP1 Hs01552599_m1 









We performed multiplex qPCR with one the above probes containing the FAM reporter dye with 
a human β-ACTIN VIC/TAMRA probe (Applied Biosystems, Life Technologies) as our 
endogenous control for each sample well. Fold change was calculated using the ddCt method. 
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Immunoblotting and detection  
Whole cell lysates were extracted using Pierce RIPA buffer (Thermo Scientific) supplemented 
with protease/phosphatase inhibitors (Thermo Scientific) on ice.  Lysates were transferred to 
1.5mL micro-centrifuge tubes, gently agitated by rocking at 4oC for 30 minutes, and spun down 
for 20 minutes at max speed in a microcentrifuge.  The cell suspension was removed and 
protein concentration was determined using the Pierce BCA Protein Assay Kit (Life 
Technologies).  Protein detection was performed using standard SDS-PAGE electrophoresis in 
reducing conditions followed by transfer and immunoblotting.  After transfer, nitrocellulose 
membranes were blocked with 3% milk in TBS-T and incubated with primary antibodies 
overnight.  Primary antibodies included MFN1 (Proteintech, 13798-1-AP, 1:250), MFN2 (Abcam, 
ab56889, 1:250), OPA1 (BD Transduction Laboratories, 612606, 1:100), GAPDH (Life 
Technologies, AM4300, 1:5000), DRP1 (DLP1, BD Transduction Laboratories, 611112), p-
DRP1 S616 (Cell Signaling, 4494, 1:250), p-DRP1 S637 (Cell Signaling, 6319, 1:250), TOMM20 
(Abcam, ab56783, 1:500), α-Tubulin (Invitrogen, 32-2500, 1:200) and CytC (GeneTex, 
GTX62145, 1:5000).  Membranes were washed and incubated with secondary antibodies, HRP 
anti-rabbit (Promega, W4011, 1:5000) and HRP anti-mouse (Promega, W4021, 1:15,000) for 1 
hour, after which proteins were detected using chemoilluminescence.      
 
Generation of stable hESC lines expressing lentiviral constructs 
We cloned both dominant negative Mfn2 (K109A, S110N) and Drp1 (K38A, Addgene 26049) 
constructs into the pLVX-EF1α-IRES lentiviral vector system containing the ZsGreen1 (Clontech 
631982) or mCherry reporter (Clontech 631987).  Lentiviral particles were produced by 
transfecting individual expression vectors with the third generation packaging plasmids into 
293T cells using Lipofectamine 3000 reagent (Life Technologies).  After 48 hours, viral 
supernatants were collected and concentrated by ultracentrifugation at 25,000rpm using the 
SW-80 rotor and the L8-80M Beckman ultracentrifuge.  Pelleted virus was re-suspended in 
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hESC media and viral titers were determined using NIH-3T3s.  hESCs were transduced with 
concentrated viral supernatants as follows.  hESCs were plated at 25,000cells/cm2 in matrigel-
coated 48-well plates (Falcon) and allowed to attach for 1 day in hESC media.  hESC media 
was removed and replaced with concentrated viral supernatant and 6µg/mL polybrene (Sigma) 
and incubated overnight.  Media containing viral particles was removed and hESCs were 
trypsininzed and re-plated onto feeder plates containing MEFs in normal hESC renewing 
conditions as described previously.  After approximately one week, cells were sorted using 
FACS (BD Influx, BD Biosciences) based on reporter activity and cultured in normal renewing 
conditions.     
 
BrdU incorporation 
The APC BrdU kit (BD Biosciences) was used to detect proliferation.  hESCs were incubated for 
1 hour with 10µM BrdU and treated per manufacturer’s instructions.  Using a fluorescent 
antibody against BrdU, stained cells were run through a flow cytometer (LSRII, BD 
Biosciences).    
 
Annexin V staining  
The Annexin V PE Apoptosis kit (BD Biosciences) was used to detect apoptosis per 
manufacturer’s instructions.  
 
Determination of intracellular Ca2+ using Indo-1 AM 
Cells were exposed to 1uM of Indo-1 dye for 60 minutes at 37oC in SFD media supplemented 
with ascorbic acid and MTG (SFD+) as described previously. Cells were washed, lightly 
dissociated with Accutase, and washed with PBS without Mg2+ and Ca2+. Cells were then re-
suspended and kept in SFD+. Cell suspensions were kept in a 37oC water bath at all times, 
even during sample collection. Samples were run through a flow cytometer (LSRII) equipped 
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with a 355nM excitation laser. The average fluorescent intensity ratio (R) of bound to free Indo-1 
(405nm/485nm emission) represented baseline levels. We spiked identical, resting cell 
suspensions with 5uM ionomycin to generate maximal fluorescence intensity ratios (Rmax) and, 
independently with 5mM EGTA to generate zero fluorescence intensity ratios (Rmin). The 
following equation was then used to calculate intracellular Ca2+ levels with a dissociation 
constant (Kd) of 210nM based on previous studies [207]: 
[Ca2+] (nM) = Kd x (R-Rmin)/(Rmax-R) 
 
Mitotracker Green stain  
On the day before cell harvesting, cells were plated onto Matrigel coated 6-well plates. Cells 
were incubated at 37oC with media containing 5nM Mitotracker Green (a higher does of 50nM 
was also tested with similar results). After 30 minutes, cells were washed with PBS, trypsinized 
and analyzed by FACS (LSRII) using a 488nm laser.    
 
Statistical analysis 
Prism7 (Graphpad) was used to calculate statistical analysis. We performed a two-tailed, 
unpaired student’s t-test. Welch’s correction was used in instances where the F-test revealed a 
significant difference in variance between samples. For experiments where we compared more 
than 2 groups, one-way ANOVA was performed followed by Bonferonni’s multiple comparison 








2.4. Results  
 
2.4.1. Mitochondrial morphology in mouse embryonic stem cells 
 
In order to understand the role of mitochondria in PSCs and their derivatives, we first 
visualized mitochondria by microscopy. We compared mitochondrial morphology in two murine 
embryonic stem cell (mESC) lines (CCE and MM13) to differentiated cells that we cultured for 7 
days in 5µM retinoic acid (Figure 2.1A). Mouse ESCs in renewing conditions expressed 
pluripotency-associated transcription factors Oct4 and Sox2 and exhibited peri-nuclear and 
globular mitochondria, consistent with previous results. In contrast, after differentiation, which 
we confirmed by the loss of Oct4 and Sox2, cells displayed filamentous, elongated mitochondria 
with a significant increase in aspect ratio, a measure of mitochondrial length (Figure 2.1A-B). 
These data suggest that mitochondrial morphology during embryonic stem cell development 





Figure 2.1.  Mitochondrial morphology in mESCs.  (A) Representative images from mouse 
ESC lines CCE and MM13 stained with Mitotracker Red to reveal mitochondria.  Top panel 
displays undifferentiated mESCs; bottom panel shows cells differentiated for 7 days.  
Expression of Oct4 and Sox2 indicates presence or absence of pluripotency. (B) Quantification 
of mitochondria as shown by aspect ratio as a measure of mitochondrial length and form factor 
and area weighted form factor to indicate complexity. Data represent >10 images from three 
independent experiments. *p<0.05. **p<0.01. Error bars represent standard error of the mean 
(SEM). Scale bar = 10µm.       
    
 
We next determined whether mitochondrial morphology reflects distinct developmental 
states between (naïve) mESCs and (primed) mEpiSCs, which differ in both pluripotentiality and 
energy production. We found that mitochondria of mESCs and mEpiSCs were similar in shape, 
location, and abundance (Figure 2.2), although it is possible that higher resolution microscopic 
studies might resolve subtle differences as shown in a previous study [127]. Together, these 
studies indicate that mitochondrial morphology is similar between the two different cell types 
that reflect distinct pluripotent states. Of note, mESCs and mEpiSCs generate energy differently 
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yet retain similar shapes, suggesting that mitochondrial morphology is not a reflection of 
metabolic state, but rather a general pluripotent stem cell characteristic. It may also be 
important to note that we saw no difference in mitochondrial morphology between live and fixed 




Figure 2.2. Mitochondrial morphology in different pluripotent states.  Representative 
images from two independent experiments of live mouse ES and EpiSCs stained with 
Mitotracker Red dye.  Scale bar = 10µm.             
 
2.4.2. Mitochondrial morphology in human embryonic stem cells  
 
Human ESCs resemble mEpiSCs with respect to cell morphology, culture conditions 
required to maintain their self-renewing capacity, expression of pluripotency-associated 
transcription factors, and epigenetic features [15]. Published studies suggest that hESCs have 
mitochondrial shape and spatial distributions similar to mESCs and mEpiSCs with short, 
fragmented mitochondria that are ‘immature’ with undeveloped cristae with indistinct, lucent 
inner mitochondrial membranes [208-210]. However, these studies use low-resolution imaging, 
they include no assessment of mitochondria in live cells, and they employ treatments with harsh 
fixatives that could themselves alter or destroy mitochondrial structure.   
In contrast, using measurements in live cells, we discovered renewing hPSCs contain 
elongated, filamentous mitochondria that localized throughout the cytoplasm (Figure 2.3A).  
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Specifically, we found that by fixing cells with 4% PFA after treatment with Mitotracker Red dye 
to stain mitochondria, a commonly used method, mitochondrial structure was severely 
compromised. Staining of live hPSCs, both in hESCs (RUES2) and iPSCs, generated from 
human dermal fibroblasts (HDF-iPS), with Mitotracker Red dye indicated the presence of 
elongated mitochondria (Figure 2.3B-C). Direct comparison of images, obtained under identical 
conditions of staining and without fixation, revealed differences in mitochondrial morphology in 
mouse and human with hESCs exhibiting mitochondria with a greater mitochondrial length after 
quantification (Figure 2.3C). The observed differences in mitochondrial morphology and location 
among different pluripotent cell types argue against a relationship between mitochondrial shape 
and pluripotency, but could identify distinct functions of mitochondria in different pluripotent cell 




Figure 2.3. Mitochondrial morphology in human ES cell lines. (A) Mitochondria visualized 
by Mitotracker Red dye in live cells and cells fixed with 4% PFA. (B) Live cells stained with 
Mitotracker Red dye and quantified by direct measurement of mitochondrial length in > 10 
images from two independent experiments. (C) Comparison of mitochondria in mouse and 
human ESC quantified from > 10 images using Image J. Data represent two independent 





2.4.3. Mitochondrial morphology in embryonic stem cells and their progeny 
 
To understand if mitochondria change their shape with differentiation in human PSCs, 
we first validated the efficiency of previous published directed differentiation protocols.  We 
differentiated hESCs to all three germ layers, DE, NE, and MD as follows. DE generates organs 
of the respiratory system, GI tract, and organs important for endocrine and immune function. DE 
induced in vitro using high concentrations of ActivinA to mimic Nodal signaling during 
gastrulation results in a near homogenous culture of CXCR4+/cKIT+/FOXA2+ cells (Figure 2.4) 
[62]. Heart, muscle, bone, cartilage, kidney, skeletal muscle and hematopoietic precursors 
derive from MD. MD induction, as defined by NKX2.5, TBX3, and PDGFRα, requires low 
concentrations of ActivinA and high BMP4 [206]. NE (PAX6+/SOX2+/SOX1+), the epithelium 
that generates the nervous system, is induced by inhibition of TGFβ and BMP signaling [211]. 
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Figure 2.4. Schematic of hESC differentiation.  hESCs that express pluripotency markers 
OCT4 and SOX2 differentiated to DE, NE, and MD. Validation of lineage specification was done 
by qPCR with samples from three independent differentiations and by protein expression either 
by cell surface marker expression by FACS or immunofluroescent staining. Protein expression 
images and FACS plots are representative of at least 3 experiments. Error bars represent SEM.   
    
 
The directed differentiation protocols that we used yielded lineage specified cells in high 
purities. Because cell fixation disrupted mitochondrial structure, we decided to image 
mitochondria in live cells. By manually measuring mitochondrial lengths per field of view using 
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Image J software (NIH), we compared mitochondrial lengths between hESCs and the three 
germ layers (Figure 2.5A). Uniform mitochondrial fragmentation occurred in DE, but not in NE or 
MD (Figure 2.5B). These results suggest a germ layer-specific requirement for mitochondrial 
fragmentation in DE specification. These morphological variations of mitochondria in hESCs and 
lineage specified cells differed from what we observed with mouse ESCs. 
 
 
Figure 2.5. Mitochondria morphology changes in hESC differentiation. (A) Mitochondria 
stained with Mitotracker Red in hESCs and in cells differentiated to DE, NE, and MD. (B) 
Quantification of lengths of individual mitochondrial by direct measurement. Data are 
representative of > 10 images from two independent experiments. *p<0.05. Error bars represent 
SEM. Scale bar = 10µm.          
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Previous data from other labs and ours reported mitochondrial elongation with 
differentiation in mESCs (Figure 2.1) [208]. These experiments employ random differentiation 
and focus on the loss of pluripotency markers (i.e. Oct4 and Sox2) to identify differentiated cells 
rather than directed differentiation methods that generate specific cell types, identified by 
lineage specific markers. Using directed differentiation methods to generate DE cells in high 
purity, we discovered mitochondrial length decreased in DE-specified hESCs (Figure 2.5).   
To address the possibility of species-specific differences in mitochondrial morphology of 
differentiated ESCs, we examined mouse DE cells. We differentiated the mESC line MM13 in 
serum-free medium supplemented with a high concentration of ActivinA, and achieved DE 
development, albeit at a lower efficiency than hESC-derived DE. Interestingly, cells co-stained 
with Mitotracker Red, Sox2, and Foxa2 revealed little change in mitochondrial length among 
Foxa2 positive cells as compared to pluripotent cells (Figure 2.6A-B). These results suggest that 
mitochondrial length does not change in a similar way in mouse and human ES differentiation to 
DE. However, this initial study would not catch any dynamic changes that might occur 
throughout differentiation. For instance, mitochondria in (naïve) mouse ESCs might start 
globular and punctate, elongate during an early stage of differentiation, and fragment in DE 
specified cells. If this were the case, it would suggest that TGF-β signaling favors mitochondrial 
fragmentation in both species. It will be important to observe mitochondria in live mouse 
embryos to determine if mitochondrial fragmentation in DE is an in vitro artifact or a relevant 




Figure 2.6. Mitochondrial morphology in mESC-derived DE.  (A) Mitochondria stained with 
Mitotracker Red and fixed. Immunofluorescence staining of Foxa2 indicate the presence of DE 
specified cells. (B) Quantification of mitochondrial length in images calculated by aspect ratio.  
Data represent > 10 images from two independent experiments. Error bars represent SEM. 
Scale bar = 10µm.             
   
 
2.4.4. Mitochondrial fusion factors in human embryonic stem cell-derived endoderm, 
neuroectoderm, and mesoderm 
 
Mitochondrial fusion and fission events regulate changes in mitochondrial shape.  
Mitochondrial fusion, mediated by Mfn1/2 and Opa1, facilitates the transmission of mitochondrial 
membrane potential, enables mixing of mitochondrial DNA gene products, and allows 
mitochondria to escape autophagy during starvation conditions [97-102]. To understand the 
regulation of fusion in hPSCs and their derivatives, we examined the expression of the 
components of the fusion machinery. Using quantitative PCR (qPCR), we observed a modest 
reduction of MFN1, MFN2, and OPA1 mRNA, indicating a decrease in the overall fusion 
machinery during hESC differentiation to DE (Figure 2.7A).  Protein expression of MFN2 
decreased in DE (Figure 2.7B-C), but not in NE or MD, suggesting that a loss of fusion occurs 




Figure 2.7. Expression of mitochondrial fusion machinery in hESCs and lineage specified 
cells. (A) Changes in transcription of fusion genes shown by qPCR. n=3. Error bars represent 
SEM. (B) Expression levels of fusion proteins in whole cell lysates from different cell types by 
western blot. (C) Quantification of WB images using Image J software. Data represent three 
independent experiments. *p<0.05. Error bars represent SEM.       
 
 
2.4.5. Ca2+ levels  
 
Since Mfn2 and mitochondrial fusion facilitate calcium (Ca2+) buffering [35] and Ca2+ 
signaling in DE promotes left-right asymmetry at the node in vivo [67], we speculated that the 
mitochondrial fragmentation we observed in DE could result in elevated Ca2+ levels. We 
examined Ca2+ levels in hESCs and in lineage specified using Indo-1, a cell permeable dye that 
binds free Ca2+, detectable in both bound and free states through UV excitation and flow 
cytometry. We calculated intracellular Ca2+ levels using the ratio of bound to free Indo-1 at 
resting, zero, and saturating conditions (Figure 2.8). We discovered intracellular Ca2+ levels 
were ~1.8 fold higher in DE compared to hESCs. Interestingly, Ca2+ levels did not change in NE 
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or mesoderm MD. These data suggest Ca2+ levels increase specifically during DE lineage 
specification implicating Ca2+ as an important second messenger during DE differentiation.    
 
 
Figure 2.8. Ca2+ levels using Indo-1 AM ratiometric dye. Calculated intracellular Ca2+ levels 
in hESCs, DE, NE, and mesoderm MD.  n=3. *p<0.05. Error bars represent SEM.                    
 
 
2.4.6. Mitochondrial fission  
 
  Mitochondrial fission occurs during cell division, apoptosis, mitophagy, and cytoskeletal 
transport of mitochondria [108-111]. Given that during DE specification mitochondria fragment, 
we monitored expression levels of known fission effector molecules. By mRNA, expression of 
DRP1 and its recruitment factor FIS1 remained similar between hESCs and the three germ 
layers (Figure 2.9A). The expression of SMCR7 and SMCRL, the genes encoding Drp1 
recruitment factors MiD49 and MiD51, respectively, were both up-regulated in MD. Only 
expression of SMCR7 was induced in DE. Protein expression analysis revealed similar levels of 
total DRP1 in hESCs and differentiated cells (Figure 2.9B, C). Exquisitely post-translationally 
regulated, DRP1 has two phosphorylation sites at serine 637 and serine 616, which are 
inhibitory and activating marks, respectively [109, 115].  Phosphorylation at S637 is PKA-
dependent and was only detectable after PKA activation by forskolin treatment (Figure 2.9D). 
Interestingly, we found higher expression of phospho-DRP1 S616 in hESCs, NE, and MD 
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compared to DE (Figure 2.9C). This result was surprising since mitochondrial remain elongated 
in hESCs, NE, and MD. These data suggest a more complex, dynamic balance between fission 
and fusion in hESCs and their derivatives. 
 
Figure 2.9. Expression of mitochondrial fission machinery. (A) Transcript levels of fission 
genes in hESCs, DE, NE, and MD. (B) Expression of total DRP1 and phosphor-DRP1 S616 in 
whole cell lysates and quantification using densitometry (C). (D) Expression of phospho-DRP1 
S637 detected only after treatment with forskolin. n=3. *p<0.05. Error bars represent SEM.   
 
2.4.7. Mitochondrial morphology during cell division  
 
 Human ESCs rapidly divide due to a short G1 phase of the cell cycle [212]. Since Drp1 
activation facilitates mitochondrial fragmentation and equal segregation during cell division 
[109], we speculated that the expression of the activating phosphorylation mark at serine 616 in 
hESCs resulted from a high number of dividing cells in our cultures. We therefore expected 
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mitochondria in dividing hESCs to exhibit fragmented mitochondria, consistent with other 
eukaryotic cell types. By assessing mitochondrial morphology in live hESCs by Mitotracker Red 
staining, we found that mitochondria remain elongated in hESCs, throughout all stages of 
mitosis (Figure 2.10A). This phenomenon appeared to be specific to hESCs, since mitochondria 
in dividing DE and NE both showed signs of mitochondrial fragmentation (Figure 2.10B). The 
resistance to fragmentation we observed suggests a role for mitochondrial elongation in the 
maintenance of hESCs. Alternatively, proper partitioning of mitochondria during cell division in 
hESCs might be a result of another mechanism that may involve the cytoskeleton, as it occurs 












2.4.8. DRP1 compartmentalization 
 
From these data, it seems unlikely that the phosphorylation at S616 resulted from 
activated DRP1 in rapidly dividing cells. From our previous expression analysis, we also know 
that the lack of fragmentation was not influenced by phosphorylation at serine 637, as it was 
undetectable in hESCs and all three germ layers (Figure 2.9D). In addition to its post-
Figure 2.10. Mitochondrial 
morphology in dividing hESCs. (A) 
Representative images of hESCs from in 
all stages of mitosis. (B) Live DE and NE 
cells in mitosis. Data are representative 
of 5-10 cells in each stage of mitosis.       	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translational modifications, DRP1 localization within the cell provides some insight into its 
activity as a fission effector protein. During mitochondrial fission, DRP1 is recruited to 
mitochondria where it forms oligomers at the mitochondrial scission site [108, 116, 117]. To 
assess DRP1 compartmentalization within the cell that will provide a sense of its activity, we 
imaged cells co-stained with Mitotracker Red and DRP1 (Figure 2.11A). Here, we fixed cells 
with methanol to better preserve mitochondrial structure. We also stained cells with FOXA2 to 
ascertain DE specified cells. Our co-localization analysis using Image J software, represented 
by Pearson’s correlation coefficient, indicated that DRP1 associated with mitochondria more 
strongly in DE compared to hESCs (Figure 2.11B). These data, combined with previous 
expression analysis, suggest that although phospho-DRP1 S616 is expressed by hESCs, it 
might not be fulfilling its activating function. The effect of phospho-DRP1 S616 may therefore 
rely on the upstream kinase or depend on cellular context rather than expression. Published 
data also support this argument: overexpression of phosphomimetic DRP1 S616D in HeLa cells 
did not alter mitochondrial morphology [214]. Nonetheless, DRP1 co-localization to mitochondria 
in DE suggests its involvement in the mitochondrial fragmentation observed in DE. Confirmation 
of DRP1 localization with mitochondria by subcellular fractionation between hESCs and DE 




Figure 2.11. DRP1 recruitment to mitochondria. (A) hESCs, DE, NE, and MD cells co-stained 
with Mitotracker Red, DRP1, and FOXA2. (B) Quantification of values calculated from Pearson’s 
correlation coefficient. Data represent > 10 images from three independent experiments. 




2.4.9. Mitochondrial morphology during endoderm specification           
 
In DE, mitochondria fragment, express lower levels of MFN2, and exhibit differential 
regulation of DRP1 phosphorylation and compartmentalization. Without directly measuring 
mitochondrial fusion and fission, these data suggest a shift in balance toward mitochondrial 
fission in DE that may explain the mitochondrial fragmentation. However, these data might 
represent a steady state achieved after 4 days of differentiation rather than an ongoing process, 
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offering an explanation for the loss of DRP1 activation during DE specification as shown by 
expression of phospho-DRP1 S616. To understand the kinetics of mitochondrial fragmentation 
during DE specification, we imaged mitochondria in live cells at each day of differentiation. We 
found that mitochondria fragment very early, at day 2 of differentiation. Visually, mitochondria in 
cells at day 2 of differentiation appeared more punctate and peri-nuclear in localization as 
compared to hESCs or day 1 cells (Figure 2.12A, B). The uniform fragmentation persisted 
throughout differentiation as shown in day 3 and day 4 cells. Quantification indicated that 
mitochondrial length decreased at day 2 of differentiation and remained reduced in day 3 and 
day 4 cells, consistent with the visual representation. Interestingly, in this differentiation protocol, 
ActivinA is added to the cells starting at day 1 and therefore at day 2, cells have been exposed 
to ActivinA for only 24 hours. These data suggest that mitochondrial fragmentation responds to 




Figure 2.12. Kinetics of mitochondrial fragmentation during DE specification. (A)  
Representative images from three independent experiments of live cells stained with Mitotracker 
Red dye and imaged at each day of differentiation. (B) Quantification of individual mitochondria 
from > 10 images depicted in A. *p<0.05. **p<0.01. Error bars represent SEM. Scale bar = 
10µm.   
 
Mitochondrial fusion and fission events occur very rapidly, detectable among individual 
organelles within one minute [103]. Since we found that mitochondria fragment after exposing 
the cells with ActivinA within 24 hours, we refined our time-course even further focusing on 
mitochondrial morphology immediately after ActivinA addition. Without measuring mitochondrial 
dynamics in real time, we chose time-point increments equivalent to at least one hour in order to 
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feasibly image the cells and to catch the time at which the mitochondria begin to fragment. We 
measured mitochondrial length and complexity in images taken 1, 3, 6, and 12 hours after 
ActivinA addition. We discovered mitochondrial length and network complexity significantly 
decreased after 12 hours of exposure (Figure 2.13A-B). Day 1 and day 2 cells were used as 
controls for elongated and fragmented mitochondria, respectively. These data suggest acute 
mitochondrial fragmentation in the early stages during DE specification. In order to determine 
what factors of the fusion/fission machinery promote the observed changes in mitochondrial 
shape, we evaluated the expression levels of OPA1, MFN2, total and phosphorylated forms of 
DRP1 (Figure 2.13C-D). We detected similar levels of OPA1 over time and observed a slight 
decrease in MFN2 protein after one day of differentiation. Total DRP1 levels remained 
unchanged and phospho-DRP1 S616 decreased similarly to MFN2, possibly reflecting a decline 
in cell division that typically coincides with differentiation. Interestingly, we discovered an 
increase in phospho-DRP1 S637 after 3 hours of ActivinA stimulation that remained 
undetectable in cell lysates from other time-points except when treated with forskolin (Figure 
2.13D).  Phospho-DRP1 S637, well defined as an inhibitory mark [115, 215], also activates 
DRP1 when phosphorylated by CAMK1α [216]. Together, these data suggest that DRP1 
activation, detectable at 3 hours post ActivinA addition, drives the mitochondrial fragmentation 












Figure 2.13. Effects of Nodal signaling on mitochondrial morphology and dynamics.  
(A) Images of live cells taken after supplementation with ActivinA at times indicated. (B) 
Quantification of mitochondrial length and network of > 10 images represented in A from three 
independent experiments. *p<0.05. **p<0.01. ***p<0.001. ****p<0.0001. Error bars represent 
SEM. Scale bar = 10µm. (C) Schematic of DE differentiation and protein expression in whole 
cell lysates extracted from cells throughout DE differentiation.  (D) Expression of phospho-DRP1 
S637 in whole cell lysates.  Forskolin treatment, that drives PKA-dependent phosphorylation of 
DRP1 at S637, was used as a positive control. Data in C and D are representative of two 
independent experiments.         
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The acute mitochondrial fragmentation observed at 12 hours suggests changes in 
mitochondrial morphology occur early in differentiation. Phosphorylation of DRP1 at S637 that 
appeared prior to fragmentation indicated that DRP1 promoted early mitochondrial shape 
changes. Interestingly, uniform expression of DE-specific markers typically appears several 
days after ActivinA addition [62]. Indeed, the induction of the endoderm-specific transcriptional 
network and repression of pluripotency-associated genes occurred after mitochondrial 
fragmentation observed between days 1 and 2 of differentiation (Figure 2.14).  At this time, 
expression of DE pioneer transcription factor, FOXA2, was induced in less than 20% of the 
cells. Together, these data suggest that mitochondrial fragmentation facilitates DE specification 





Figure 2.14. Protein expression of transcription factors throughout DE induction. Number 
of cells expressing FOXA2, OCT4, and SOX2 by immunofluorescence staining at each 
timepoint indicated. Data represent two independent experiments.      
 
 
Whether mitochondrial fragmentation is a cause or effect of differentiation remains 
unknown. However, the timing of fragmentation, which occurs prior to induction of the 
endoderm-specific gene regulatory network and after ActivinA addition, suggests fragmentation 
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promotes endoderm specification downstream of Nodal signaling. From our previous expression 
analysis, we speculated that MFN2 and DRP1 are most likely involved, therefore warranting 
further studies that inhibit their functions.  
 
2.4.10. Inhibition of mitochondrial dynamics in human embryonic stem cells 
 
To investigate the relationship between mitochondrial morphology and mitochondrial 
dynamics in stem cell maintenance and cell fate specification, we developed models to block 
the activity of DRP1 and MFN2. Both MFN1/2, OPA1, and DRP1 are large GTPases belonging 
to the dynamin superfamily that share common protein domains [217]. A widely used mutation 
in the GTPase domain of dynamin (K44A) blocks nucleotide binding and inhibits its effector 
function [218]. Because dynamins typically form oligomers, overexpression of the mutant gene 
product confers dominant-negative activity. To understand if mitochondrial morphology, 
coordinated by fusion and fission events, affect stem cell maintenance and differentiation, we 
generated lentiviral constructs of MFN2 and DRP1 with the analogous dynamin K44A mutation.  
We first validated these constructs in HeLa cells and found that both constructs affected 
mitochondrial morphology and sub-cellular localization (Figure 2.15A and D). Overexpression of 
wild type Mfn2 induced mitochondrial peri-nuclear clustering that was even more pronounced in 
cells overexpressing a Mfn2 dominant negative (DN) construct. In the hESC RUES2 cell line, 
however, overexpression of either Mfn2 construct did not result in detectable shape or location 
differences. Transcript and protein levels of Mfn2 in transduced hESCs confirmed its 
overexpression (Figure 2.15B-C). Overexpression of a dominant negative Drp1 K38A (Drp1 DN) 
construct in HeLa cells also resulted in morphological changes of mitochondria (Figure 2.15D). 
Cells expressing the construct contained peri-nuclear, globular mitochondria or extremely 
elongated mitochondria greater than 10 microns in length. In RUES2 cells overexpressing the 
Drp1 DN mutant gene product, some cells displayed similar phenotypic mitochondrial 
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characteristics of mitochondria as shown in HeLa cells. Expression of mRNA and protein was 
higher in DN Drp1-transduced hESCs, verifying Drp1 overexpression.   
 
 
Figure 2.15. Lentiviral construct validation in HeLa cells and RUES2 cells. (A) and (D) 
HeLa cells and RUES2 cells transduced with Mfn2, Mfn2 DN, and Drp1 DN constructs; 5-10 
images were analyzed for each group. Scale bar = 10µm. B and E. Transcript levels of Mfn2 
and Drp1 in RUES2 cells transduced with lentiviral constructs. (C) and (F) Protein expression of 
whole cell lysates from transduced RUES2 cells as detected by western blots. 
 
 The negligible effects seen by overexpressing Mfn2 and Mfn2 DN implied that Mfn2 
played an insignificant role in mitochondrial elongation in hESCs. Therefore, to determine the 
role of mitochondrial dynamics in differentiating hESCs, we chose to inhibit Drp1 in hESCs and 
their derivatives using the dominant negative construct (Drp1 K38A). Mouse ESCs lacking Drp1, 
established from Drp1-/- embryos, proliferate more slowly than controls and maintain a healthy 
colony appearance, although this study did not include a thorough assessment of stem cell 
maintenance and pluripotency [114]. Mouse Drp1-/- embryos develop until ~E11.5, through the 
ESC stage, suggesting that Drp1 is dispensable for gastrulation during development in vivo; 
however, the pluripotent potential of ESCs in vitro generated from Drp1-/- embryos remains 
unclear. To determine the importance of Drp1 in the maintenance of pluripotency in human 
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ESCs, we first tested the expression of pluripotency-associated genes OCT4, SOX2, and 
NANOG in hESCs transduced with Drp1 DN lentiviral particles. We discovered similar transcript 
levels among cells transduced with Drp1 DN and the empty vector (EV) control (Figure 2.16A).  
We assessed stem cell maintenance by evaluating apoptosis and proliferation in control and 
Drp1 DN cells. We detected no changes in apoptosis indicated by AnnexinV staining (Figure 
2.16B) or in proliferation assessed by BrdU incorporation (Figure 2.16C). These results suggest 
Drp1 function is not required for stem cell pluripotency or stem cell maintenance in human 
ESCs.               
 
 
Figure 2.16. Effect of Drp1 inhibition in hESCs. (A) Analysis of mRNA transcripts of 
pluripotency genes in cells from three independent experiments transduced with empty vector 
(EV) or Drp1 K38A constructs. (B) Annexin V positive cells determined by flow cytometry. (C) 
BrdU incorporation after 1 hour of treatment. n=2. Error bars represent SEM.           
 
 
Our data indicate DRP1 function is dispensable for maintaining hESCs in vitro. Whether 
it affects the ability of stem cells to differentiate remains an important question, however.  Drp1 
deficiency influences the development of cells from all three germ layers. Embryos from Drp1-/-
	  62 
mice exhibit a significantly smaller body size with an underdeveloped liver, heart, and neural 
tube [114]. Therefore, we differentiated hESCs expressing either the EV or Drp1 DN construct 
to all three germ layers as described previously. We found no effect on the generation of DE, 
NE, or MD by overexpressing the Drp1 DN construct, as shown by near equivalent expression 
of markers for each respective germ layer (Figure 2.17A-C). These findings indicated that Drp1 
activity is not required for differentiation of hESCs. From our previous data, we suspected that 
the mitochondrial fragmentation in DE specification involved DRP1. However, mitochondria in 
Drp1 DN overexpressing DE cells maintained a fragmented morphology (Figure2.17 D and E) 
suggesting a Drp1-independent mechanism of mitochondrial fragmentation in DE specification.  
Since DRP1 inactivity did not inhibit mitochondrial fragmentation, the question remains whether 
mitochondrial morphology, as controlled by mitochondrial dynamics factors, affects stem cell 
maintenance, pluripotency, or differentiation.  





Figure 2.17. Differentiation effects of Drp1 inhibition in hESCs.  (A-C) Marker expression of 
hESCs, overexpressing the EV or Drp1 K38A construct, differentiated to DE, NE, or MD. (A) 
Cell surface expression of CXCR4+/cKIT+ cells and intracellular expression of FOXA2+ cells by 
flow cytometry from five independent endoderm differentiations. (B) Quantification of PAX6+ 
and SOX2+ cells counted manually after immunofluorescence staining from two independent 
experiments. (C) Cell surface expression of PDGFRα+ and KDR+ cells by flow cytometry from 
two independent experiments. (D) Representative images of EV of Drp1 K38A expressing DE.  
Scale bar = 10µm. (E) Quantification of mitochondria as shown in D was calculated from > 10 
images from two independent experiments. Error bars represent SEM.            
 
2.4.11. Mitophagy  
 
 To further understand the impact of mitochondrial fragmentation on hESC cell fate, we 
investigated other important mitochondrial functions in hESCs and their derivatives. 
Mitochondria fragment within the cell for a variety of reasons: during mitosis to promote 
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distribution of organelles to daughter cells, for mitochondrial transport throughout the cell, during 
apoptosis to promote the release of cytochrome c, and prior to mitophagy in order to isolate and 
recycle damaged mitochondria [219]. Pink-Parkin mediated mitophagy activates in response to 
mitochondria that have lost membrane potential, while the protein, Nix, encoded by the BNIP3L 
gene, excludes mitochondria from the cell during red blood cell development. Because we 
observed uniform mitochondrial fragmentation during DE specification, we speculated that DE 
cells might exhibit activated mitophagy. We first measured transcript levels of genes involved in 
mitophagy: PINK1, PARK2, and BNIP3L. In all three germ layers, we found increased 
expression of all three genes compared to hESCs by mRNA (Figure 2.18A). In contrast, when 
we profiled PINK expression by western blot, we discovered that PINK protein expression was 
actually downregulated in cells specified towards DE and NE lineages (Figure 2.18B). Since 
PINK recruits PARKIN to damaged mitochondria [220], we stained hESCs and DE with an 
antibody against PARKIN with and without CCCP treatment, which stimulates a loss in 
mitochondrial membrane potential and PARKIN aggregation on mitochondria (Figure 2.18C). In 
both DMSO and CCCP treated cells, we only observed PARKIN aggregation in CCCP-treated 
DE and not in hESCs. Combined, these data suggest that hESCs might accumulate PINK1 on 
damaged mitochondria, but lack proper PARKIN recruitment. It also indicates that DE cells, 







Figure 2.18.  Expression and aggregation of mitophagy factors.  (A) Transcript levels of 
genes encoding PINK, PARKIN, and NIX in hESCs and cells differentiated to three germ layers.  
Data represents three independent experiments. *p<0.05. Error bars represent SEM. (B) 
Western blot of PINK expression in hESCs, DE, and NE. (C) hESCs and DE were exposed to 
CCCP, fixed, and stained for PARKIN expression. Scale bar = 10µm. Data in B and C Data are 
representative of one experiment.   
 
2.4.12. Mitochondrial content  
 
 In addition to mitophagy, mitochondrial biogenesis also regulates mitochondrial content 
within the cell. Others have shown that biogenesis in early neural progenitors decreases [221], 
while biogenesis actually increases with differentiation to cardiomyocytes [222], a mesoderm-
derived cell lineage. To determine how mitochondrial content is regulated in DE cells, we 
stained cells with Mitotracker Green that specifically binds mitochondria regardless of 
membrane potential, therefore an indicator of total mitochondria within the cell (Figure 2.19A-B).  
We discovered a higher mean fluorescence intensity (MFI) in DE-specified cells compared to 
hESCs suggesting that mitochondrial mass increased in DE progenitors. There was no 
significant change in MFI in NE or MD, although NE cells consistently displayed a higher MFI 
than hESCs and MD. As mentioned previously, we found it difficult to preserve mitochondrial 
integrity using paraformaldehyde (PFA) fixation of hESCs, however, PFA fixation worked well in 
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DE, NE, and MD (Figure 2.19C). In addition, mitochondrial fractionation and visualization of 
mitochondrial protein content by silver stains of hESCs and DE revealed differences in the 
mitochondrial proteome after hESC differentiation to DE (Figure 2.19D-E). Together, these data 





Figure 2.19.  Evidence of changes in mitochondrial components in differentiated cells.  
(A) Representative FACS plot of cell types stained with a low dosage of Mitotracker Green 
(5nM). (B) Quantification of Mitotracker Green stain from three independent experiments. 
***p<0.001. Error bars represent SEM. (C) Images from live and fixed cells.  Scale bar = 10µm.  
(D) Western blot of isolated cytoplasmic (C) and mitochondrial (M) fractions from a 
representative sample. (E) Silver stain of mitochondrial fractions from hESCs and DE. Arrows 
specify differences in mitochondrial proteome between the two cell types. Data in (E) represent 














 In this study, we identified differences in mitochondrial morphology and in both 
expression and regulation of mitochondrial dynamics proteins between pluripotent stem cells 
and their derivatives. Mitochondrial morphology in mESCs differed dramatically from hESCs: 
mitochondria in mESCs appeared punctate and globular whereas hESCs contained longer and 
tubular-shaped mitochondrion. Mitochondria remained elongated in hESCs, even throughout all 
stages of mitosis. Mitochondrial fragmentation during differentiation was specific to hESC-
derived DE and occurred prior to the activation of the DE-specific genes. Our expression studies 
of fusion and fission factors indicated differential regulation of the mitochondrial dynamics 
machinery, both transcriptionally and post-translationally, between hESCs and lineage-specified 
cells. From these studies we speculated that MFN2 and DRP1 influenced the maintenance and 
changes in mitochondrial shape. However, expression of dominant negative MFN2, as a way of 
inhibiting fusion, did not affect mitochondrial elongation in hESCs. Expression of the DRP1 
dominant negative (DRP1 DN), which presumably inhibited fission activity, did not influence 
mitochondrial fragmentation. Because we were unable to alter mitochondrial morphologies in 
hESCs and in lineage specified cells, it is unclear whether the observed differences in 
mitochondrial morphology and mitochondrial dynamics has any functional relevance to stem 
cells and their early progenitors.  
  Two possibilities might explain the mitochondrial fragmentation observed in Drp1 DN 
overexpressing cells: mitochondrial fragmented in DE independent of DRP1 or expression of the 
Drp1 DN construct did not effectively inhibit DRP1 activity. Although the widely used Drp1 DN 
construct typically disrupts mitochondrial fission, these studies use transformed cell lines [113]	  
[223]. Indeed, we also discovered the Drp1 DN construct inhibited mitochondrial fission in HeLa 
cells. An alternative approach might include a knockdown method using new gene editing 
approaches such as CRISPR [224]. However, interfering with the fusion or fission machinery is 
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known to have cell-type specific effects on cell cycle progression and apoptosis [112, 114, 225], 
potentially making it difficult to create stable hESC lines that lack DRP1. If this is the case, it 
would suggest a requirement for DRP1 in stem cell maintenance, but even more sophisticated 
techniques such as using an inducible system to perform gene editing might be required to 
determine whether mitochondrial dynamics promote endoderm specification. 
Although DRP1 is the known fission effector molecule that promotes mitochondrial 
fragmentation in mammalian cells, DRP1-independent mechanisms of mitochondrial 
fragmentation also exist. In Drp1-/- MEFs, mitochondria fragment during later stages of 
apoptosis, after the release of cytochrome c, suggesting an alternate mechanism of 
mitochondrial fragmentation [123]	   [114]. Additionally, the short isoform of OPA1 also promotes 
mitochondrial fragmentation [226], although our initial expression studies did not indicate any 
changes in OPA1 expression. We were unable to determine the function of mitochondrial 
dynamics in hESCs and their derivatives, either due to the inherent biology of stem cells or 
technical difficulties; however, our initial studies still suggest that mitochondrial dynamics play a 
role in stem cells and early development representing a unique, yet important topic for the stem 
cell field.   
Since knockdown of individual fusion and fission factors results in embryonic lethality	  
[103] [114] [123]	   [124], it still remains plausible that mitochondrial morphology, influenced by 
mitochondrial dynamics, affects cell fate decisions in the early embryo. Mitochondrial dynamics 
might directly affect cell fate through their influence on second messengers or act downstream 
of activated gene regulatory networks to control the function of mitochondria in specific cell 
types. Calcium (Ca2+) represents an important second messenger that can be affected by 
mitochondrial dynamics [227]. In addition to promoting mitochondrial fusion of mitochondria, 
Mfn2 docks mitochondria to the endoplasmic reticulum, which, in turn, facilitates Ca2+ buffering.  
Elevated Ca2+, in the absence of mitochondrial fusion, has physiological consequences that 
include the inhibition of cardiomyocyte development in vitro and in vivo via Notch signaling 
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[125]. How Ca2+ signaling, downstream of mitochondrial dynamics, affects DE cells remains 
uncertain; however, our data suggest Ca2+ signaling in DE affects patterning in the early embryo 
by promoting left-right asymmetry at the node [228]. Interestingly, we found higher intracellular 
Ca2+ levels in DE compared to hESCs (Figure 2.8). These observations suggest that elevated 
Ca2+ levels might play an important role in DE, especially since Ca2+ levels remained similar in 
cells differentiated to NE and MD. As a second messenger, Ca2+ affects many signal 
transduction cascades that could potentially influence differentiation. It would be interesting to 
detect changes in Ca2+ levels during DE specification to help identify when the differences in 
Ca2+ levels first occur. If the induction of phospho-DRP1 S637 at 3 hours of Activin A treatment 
represents DRP1 activation by CAMK1α [216], a calcium-dependent kinase, then these data 
might implicate a connection between mitochondrial fragmentation and Ca2+ signaling during DE 
specification. 
In addition to providing the first evidence for a role of mitochondrial dynamics in early 
development, our data also implicate hESCs as a good cell system for studying basic 
mechanisms of mitochondrial segregation during cell division. Well described in the literature, 
mammalian cells typically fragment their mitochondria during mitosis through a process 
involving Drp1 [109, 112]. Drp1 phosphorylation at serine 616 by cyclinB-CDK1 promotes 
mitochondrial fragmentation during mitosis. CyclinB-CDK1 forms a complex with RALA and 
RALBP1 that facilitates mitochondrial fragmentation and equal segregation of mitochondria 
[122]. Disruption of this process results in chromosomal abnormalities and cell cycle defects.  
Interestingly in yeast, mitochondria segregate their mitochondria independently of Drp1 through 
the use of the cytoskeleton [213]. This active mechanism for equal mitochondrial segregation 
has yet to be described in eukaryotic cells. Since mitochondria in hESCs remain elongated 
throughout mitosis, this observation, regardless of its relevance to stem cells, offers a model in 
which to study active segregation of mitochondria in mammalian cells.  
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The resistance to mitochondrial fragmentation in hESCs might also explain other 
processes important for stem cell maintenance. Mitochondrial fission mechanisms activate prior 
to mitophagy [229], a specialized form of autophagy that degrades and recycles mitochondrial 
organelles. Two mechanisms of mitophagy have been described in eukaryotic cells: Pink-Parkin 
mediated mitophagy in response to damaged mitochondria [220], and mitophagy facilitated by 
Nix during red blood cell development [230].  When mitochondria lose membrane potential, they 
become coated in Pink1, which, via phosphorylation of Mfn2, recruits the E3 ubiquitin ligase 
Parkin that ubiquitylates mitochondrial proteins [231]. This signals the autophagosome to engulf 
damaged mitochondrion and recycle its contents. In red blood cell development, the protein Nix, 
encoded by BNIP3L, binds to LC3b through its WXXL motif and initiates degradation through 
the lysosome [232]. We discovered expression of genes in both pathways—PINK1, PARK2, and 
BNIP3L, were up-regulated in DE, MD, and NE suggesting activation of the entire mitochondrial 
mitophagy machinery during early differentiation (Figure 2.18). Although transcriptionally up-
regulated, we actually found a decrease in PINK1 protein expression in DE and NE compared to 
hESCs. These results were puzzling, however, it was shown that in healthy mitochondria, Pink1 
is degraded through the N-end rule pathway and undetectable at the protein level under healthy 
cell conditions [233]. In response to mitochondrial damage, PINK1 is stabilized on the outer 
mitochondrial membrane and recruits other mitophagy effector proteins. It is possible that 
PINK1 is stabilized on hESC mitochondrial membranes, but cannot effectively recruit other 
mitophagy effector molecules such as PARKIN.  Indeed, in one preliminary experiment, CCCP 
stimulated PARKIN aggregation in DE but not in hESCs. These preliminary data suggest that 
mitophagy is not activated in hESCs, which may have important implications for hESC 
maintenance.  
Mitochondria undergo mitophagy to regulate mitochondrial content, to control for the 
accumulation of damaged mitochondria, and during specialized developmental stages (i.e. red 
blood cell development) [219]. Another way mitochondria regulate mitochondrial content is 
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through mitochondrial biogenesis. During development, mitochondrial biogenesis initiates after 
implantation of the embryo to the uterine wall [90]. Similarly, in vitro differentiation studies using 
hESCs, generated from embryos immediately prior to implantation, indicate that mitochondrial 
biogenesis also changes with differentiation [221, 222]. We found elevated Mitotracker Green 
staining in DE cells after 4 days of differentiation suggesting that total mitochondrial content is 
higher in the DE-specified cells (Figure 2.19). We also experienced difficulty in maintaining 
mitochondrial structure after fixation in hESCs, but not in DE, NE or MD, providing more 
evidence that mitochondrial content changes with differentiation. In addition, a comparison of 
the mitochondrial proteome in hESCs versus DE showed discrete differences in the overall 
protein content in mitochondrial-isolated fractions.     
Together, the mitochondrial fragmentation observations, expression studies, Ca2+ data, 
and mitochondrial content experiments, suggest that mitochondria change in shape, content, 
and function during DE differentiation. Importantly, these data were specific to DE-specified 
cells and not general differentiation characteristics suggesting that mitochondria are somehow 
involved in DE cell fate choices, which could either be a driving force of differentiation or simply 
a consequence of DE lineage specification. Future studies testing the importance of each 
function will provide insight into their requirements during lineage specification. Whether these 
observations reflect an in vitro artifact remains unclear, however, because mESC-derived DE 
also appeared small and punctate, it would be interesting to profile mitochondrial shape in 
mouse embryos to rule out any in vitro artifact phenomena.   
Mouse and human ESCs, representing naïve and primed pluripotent states, respectively, 
differ metabolically [127], offering an explanation for the dramatic differences observed in 
mitochondrial shape. Several groups have identified methods of converting human primed 
pluripotent cells to a naïve state without the use of transgenes [16-18]. It would be interesting to 
profile mitochondrial shape and energy production from primed ESCs that have been de-
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differentiated to a naïve pluripotent state to understand if mitochondrial morphology and function 
correlates with pluripotent status. 
 Insight into the mitochondrial biology of pluripotent stem cells and their derivatives will 
allow us to gain a deeper understanding of these cells and improve directed differentiation 
techniques. A few years ago, several studies showed that in long-term culture, hESCs develop 
genomic abnormalities, which raised legitimate concerns about their therapeutic applications 
[234, 235]. This result was not surprising considering self-renewing embryonic stem cells 
represent an artificial state in vitro. Furthermore, one group profiled mitochondrial DNA deletions 
in multiple human ESC lines and found regardless of passage number, hESCs contain large 
mitochondrial DNA deletions [236]. Additionally, these DNA deletions persisted after 
differentiation. These data, combined with our preliminary mitophagy studies, indicate 
mitochondria cannot undergo proper organelle turnover in hESCs, possibly so substantial that it 
cannot be resolved in later stages of differentiation in cells capable of mitophagy. This raises 
another critical question of safety and effectiveness of hESCs and offers an explanation as to 
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3.1. Abstract  
 
The developmental fate of hematopoietic stem and progenitor cells is influenced by 
signals from the local microenvironment that regulate gene transcription. To what extent cell fate 
decisions are instructed either by environmental cues or pre-established programs remains 
unclear, as are the molecular pathways involved. In this study, we find that NR4A1, a 
transcription factor expressed by myeloid-biased long term-hematopoietic stem cells, guides the 
lineage specification of more mature multipotent progenitors in a context-specific manner.  
Nr4a1-deficient mice display a marked increase in the number of erythroid progenitors and 
precursors in the spleen, but not the bone marrow. Using NR4A1GFP reporter mice, we identify a 
previously uncharacterized population of CD71lowCD24high cells that express high levels of 
NR4A1 in the spleen. In vitro, NR4A1-expressing CD71lowCD24high cells restrict BFU-E colony 
formation while promoting the differentiation of other myeloid cell types. In vivo adoptive transfer 
of this novel CD71lowCD24high population generates exclusively myeloid lineage cells including 
erythrocytes, platelets, monocytes, and neutrophils. Moreover, transfer of Nr4a1-/- 
CD71lowCD24high cells contributes significantly more to erythrocyte and platelet populations 
compared to WT cells. CD71lowCD24high cells up-regulate NR4A1 in response to stimulation with 
prostaglandin E2, an extracellular signal known to induce myeloid cell differentiation. Thus, in 
this environmentally responsive subset of myeloid progenitors, NR4A1 integrates external 
signals to limit erythropoiesis and megakaryopoiesis in the spleen. Our work defines a new 
progenitor population, enriched in the spleen, whose cell fate is mediated by environmental 






3.2. Introduction  
 
Hematopoietic stem cells generate all blood lineages by a hierarchical process in which 
cells with the broadest range of lineage potential differentiate into daughter cells whose fates 
are more restricted. Transcriptional networks orchestrate this process by integrating internal and 
environmental signals. While some transcription factors (e.g. GATA1) have lineage-restricted 
roles[237], others play multiple roles at diverse points in hematopoietic development (i.e. 
NOTCH1) [238, 239]. 
 The orphan nuclear receptor, NR4A1 (Nur77), along with family members NR4A2 
(Nurr1) and NR4A3 (NOR1) are immediate, early response transcription factors involved in 
metabolism, growth factor signaling, apoptosis, inflammation, and the development of both 
innate and adaptive immune cells [188, 240-245]. Within this family, NR4A1 has non-redundant 
functions at several distinct stages of hematopoiesis, affecting both multipotent and committed 
cells. NR4A1 plays a role in lymphocyte development and mediates T-cell receptor (TCR)-
driven thymocyte selection [246-248]. During the later stages of myelopoiesis, NR4A1 is 
required for the generation of non-classical, patrolling monocytes that function during 
homeostasis, tissue repair, and immune surveillance [245, 249-251]. In addition to these roles in 
terminal immune cell development, NR4A1 also functions early in hematopoiesis in 
hematopoietic stem and progenitor cells (HSPCs). NR4A1 expression biases long-term 
hematopoietic stem cells (LT-HSCs) toward myeloid cell fates and is induced in a PKA-
dependent manner by prostaglandin E2 (PGE2) [187]. The role NR4A1 plays during the 
subsequent development of myeloid progenitor cells, if any, is unknown.  
Only a small fraction of bone marrow LT-HSCs express NR4A1 (<10%) whereas a large 
majority of splenic LT-HSCs (>60%) express NR4A1 at very high levels indicating LT-HSCs in 
the spleen favor myelopoiesis (unpublished). Although bone marrow and splenic LT-HSCs 
occupy similar niches and rely on CXCL12 and SCF to self-renew [152, 252], they differ in 
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potential. Splenic LT-HSCs appear to actively cycle and, unlike most bone marrow LT-HSCs, 
express CCR2, a marker of proliferating myeloid-biased stem cells [253]. The bone marrow 
contains 6-fold fewer CCR2+ LT-HSCs, consistent with their more balanced lymphoid to 
myeloid output. In addition, the spleen lacks osteoblasts, bone marrow niche cells critical for 
maintaining lymphoid progenitors [153]. Together, these data highlight the potential of splenic 
LT-HSCs to generate specific mature myeloid lineages. However, these studies do not address 
whether the spleen generates unique signals that enforce particular patterns of differentiation, 
either in the steady state or under pathophysiological stress. 
In healthy adult vertebrates, HSC differentiation occurs primarily in the bone marrow, but 
can also occur elsewhere in the body, including in the liver and spleen. Extramedullary 
hematopoiesis is largely auxiliary unless bone marrow function is compromised by myelofibrosis 
or stressed by acute infection, myocardial infarction, or blood loss [254-257]. In response to 
these hematopoietic challenges, the spleen drives emergency hematopoiesis by promoting HSC 
proliferation and differentiation to generate granulocytes, monocytes, or erythrocytes, depending 
on the effector cell type needed [253, 255, 258, 259]. Whether hematopoiesis in a healthy, 
unstressed spleen exhibits this same myeloid bias and whether the spleen supports unique 
myeloid developmental pathways are not known.  
Here we identify a novel, specialized subset of multipotent myeloid progenitors that are 
uniquely represented in the spleen compared to the bone marrow. We term these multipotent 
progenitors of the spleen (MPPS). MPPS express high levels of NR4A1, which restricts their 
megakaryocyte and erythroid potential both in vitro and in vivo, instead biasing their 
development into other myeloid cell types, including monocytes. Thus, MPPS constitute a novel 
population of splenic multipotent progenitors whose differentiation into the myeloid lineage is 




3.3. Experimental Procedures  
 
Mice 
All mice were male and originally purchased from Jackson laboratories (Bar Harbor, ME) and 
shared the C57BL/6J background. Nr4a1 knockout mice (B6; 129S2-Nr4a1tm1Jmi/J) and 
Nr4a1GFP+/- mice (C57BL/6-Tg(Nr4a1-EGFP/cre)820hog/J) were bred at Charles River 
Laboratories (Wilmington, MA) and transferred when needed. Transgenic Nr4a1GFP+/- mice 
express GFP under the control of a randomly inserted Nr4a1 promoter. Only heterozygous 
Nr4a1GFP+/- mice were used in this study and identified by the presence of the transgene using 
genotyping primers (5’ CGGGTCAGAAAGAATGGTGT 3’ and 5’ CAGTTTCAGTCCCCATCCTC 
3’). UBC-GFP mice (C57BL/6-Tg(UBC-GFP)30Sha/J) and CD45.1 (B6.SJL-PtprcaPepcb/BoyJ) 
mice were used as recipients in transplant experiments. All experiments, animal handling, and 
husbandry followed the guidelines required by the Columbia University Institutional Animal Care 
and Use Committee.  
 
Flow cytometry  
For analysis of progenitor populations, bone marrow (femur, tibia, and hip) and spleens were 
treated with ACK lysis buffer (Lonza) and washed in PBS containing 0.1% BSA (Fisher 
Scientific). Bone marrow and splenic progenitors were separated from lineage positive cells 
using the Lineage Depletion Kit (Miltenyi Biotech). Lineage negative populations were then 
stained with Aquadead (Life Technologies/Thermo Fisher Scientific) in PBS at a dilution of 
1:1000, washed in 0.1% BSA, and stained with cell surface antibodies against lineage antigens 
(Mac1, Gr1, Ter119, B220, CD3, NK1.1) and anti-Sca1, anti-cKit, anti-CD41, anti-CD16/32, 
either with anti-CD150 and anti-CD105, or anti-CD71 and anti-CD24. Please refer to Table S1 
for a complete list of antibodies used in this study. Cells were analyzed using a MACS Quant 
(Miltenyi), Fortessa or LSRII (Becton Dickinson) and sorted with an Aria (Becton Dickinson).  
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Figure 3.1. Gating scheme for the identification of defined hematopoietic progenitor 
subsets. Bone marrow and splenic progenitor populations were lineage negative (Mac1, Gr1, 
Nk1.1, CD3, B220, and Ter119) and identified using the indicated markers. Lineage-Sca1+cKit+ 
(LSKs). Megakaryocyte progenitors (MkPs). Granulocyte-macrophage progenitors (GMPs). Pre-
granulocyte-macrophage progenitors (Pre-GMs). Pre-megakayocyte/erythrocyte progenitors 




Marker Clone Vendor 
Sca1 D7 eBioscience 
cKit 2B8 Biolegend 
CD41 MWReg30 Biolegend 
CD16/32 93 Biolegend 
CD150 TC15-12F12.2 Biolegend 
CD105 MJ7/18 Biolegend 
CD48 HM48-1 eBioscience 
Ter119 TER-119 Biolegend  
Nk1.1 PK136 Biolegend  
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B220 RA3-6B2 Biolegend 
Mac1 M1/70 Biolegend  
Gr1 RB6-8C5 Biolegend  
CD3 145-2C11 Biolegend 
CD71 R17217 Biolegend 
CD24 M1/69 Biolegend 
CD44 IM7 Biolegend 
CD19 6D5 Biolegend 
CD8a 53-6.7 Biolegend  
CD4 RM4-5 Biolegend 
CD115 AFS98 eBioscience 
Ly6C HK1.4 Biolegend 
Ly6G 1A8 Biolegend 
 




Figure 3.2. Gating scheme for identifying lineage negative populations. Representative 
gating strategy of cells isolated from the bone marrow and spleen that were depleted for lineage 
positive cells. All remaining cells, including Lineage-positive cells that were not successfully 
removed, were stained with a Live/Dead indicator, antibodies against Lineage markers (Mac1, 





CFU-E and BFU-E colony formation assays 
Colony assays were performed as described previously.[261-263] For CFU-E analysis, 
nucleated bone marrow (1x105/mL) and splenocytes (2x106/mL) were plated onto Methocult 
M3234 (Stem Cell Technologies) containing 3U/mL EPO (Peprotech) and placed into a 
humidified chamber under normoxia (21% O2). The presence of small, rose-colored colonies 
were counted 2 days after plating using an inverted microscope. BFU-Es were scored 10 days 
after nucleated bone marrow and splenocytes were plated onto Methocult M3234 containing 
3U/mL EPO and 50ng/mL SCF (Peprotech).        
 
Peripheral blood analysis 
Blood samples were collected in EDTA coated capillary tubes (Sarstedt) and measured 
immediately for complete blood counts that included hematocrit levels and red blood cell counts 
using the Hemavet HV950 Multispecies Analyzer (Drew Scientific). For analysis by flow 
cytometry, samples were spun down in a microcentrifuge at 100g for 10 minutes. The upper 
aqueous layer was removed, washed with in 0.1% BSA PBS containing EDTA, and stained with 
anti-Ter119 and anti-CD41 antibodies to identify erythrocytes and platelets, respectively.  The 
remaining blood sample was then treated with ACK lysis buffer, immediately washed in 0.1% 
BSA PBS and stained with antibodies against lineage markers (Mac1, Ly6C, Ly6G, CD115, 
CD3, CD4, CD8, and CD19).     
 
Analysis of mature cell subsets in primary and secondary lymphoid organs 
Mouse organs (bone marrow, spleen, thymus and lymph nodes) were dissected and dissociated 
without enzymes.  Cells were washed in 0.1% BSA PBS containing EDTA and either 




BFU-E proliferation assay  
Splenic BFU-Es (Lin-Sca1-cKit+CD16/32-CD41-CD71lowCD24low) were sorted and immediately 
cultured in round bottom 96-well plates containing StemSpan SFEM (Stem Cell Technologies) 
supplemented with Glutamax and MEM non-essential amino acids (Thermo Fisher Scientific) 
and 100ng/mL SCF, 40ng/mL IGF-1, and 2U/mL EPO (Peprotech) with or without 100nM 
dexamethasone (Sigma).[264] Live cells counts were determined by the absence of propidium 
iodide (Sigma) staining via flow cytometry.  
 
Phenylhydrazine treatment of mice  
Three-month-old WT or Nr4a1-/- mice were given 60mg/kg phenylhydrazine on sequential days 
(day 0 and day 1). Starting at day 2, peripheral blood was collected and immediately analyzed 
for hematocrit levels (red blood cell volume) and red blood cell counts.   
 
In vitro stimulation 
Bone marrow cells and splenocytes were dissociated and depleted of mature, lineage positive 
cells as done for progenitor cell analysis. Cells were washed in 0.1% BSA/PBS and plated in 
RPMI basal medium without phenol red (Gibco) with added supplements: SCF (20ng/mL), G-
CSF (10ng/mL) (Peprotech), LPS (1µg/mL), or PGE2 (1µM) (Sigma). Cell suspensions were 
incubated for 1hr at 37oC, washed in 0.1%BSA/PBS and stained with cell surface antibodies for 
progenitor populations as explained above.   
 
Methylcellulose assay 
Progenitor cells sorted from the bone marrow and spleens of Nr4a1GFP+/- mice were plated at a 
density of 250-500 cells per well in triplicate onto 6-well plates containing Methocult M3234 
(Stem Cell Technologies) with 50ng/mL SCF, 20ng/mL IL-3, 20ng/mL IL-6, 10U/mL EPO, 
10ng/mL TPO, and 10ng/mL Flt-3 ligand (Peprotech). After 10-12 days in culture, 96 images 
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were taken of each individual well using a Zeiss AxioObserver.Z1 inverted microscope and 
patched together using Zen software. Colony area (mm2) was calculated by manually measuring 
individual colonies from each tile scan image using ImageJ software. A bright-field, inverted 
microscope (Olympus CK2) was used to characterize individual colonies.  
 
Single cell colony assay 
Five splenic L-S-K+CD41-CD16/32-CD71lowCD24high cells that were either NR4A1GFP+ or 
NR4A1GFP- were sorted directly into 96-well plates containing Methocult M3234 with 
supplements (SCF, IL-3, IL-6, EPO, TPO, and Flt3-ligand). Five cells were plated to increase 
the probability of each well containing only one colony, calculated based on prior experiments in 
which 1 in every 6-7 MPPS generated a colony. Five days after sorting, individual wells were 
analyzed for the presence of small colonies. Any well containing more than one colony was 
excluded from the analysis. After 10-12 days in culture, each colony was dissociated and 
stained with Aquadead (Life Technologies/Thermo Fisher Scientific) and antibodies against 
myeloid cell surface markers (anti-CD41, anti-Ter119, anti-Gr1, anti-Mac1).     
 
In vivo adoptive transfer experiments 
Recipient UBC-GFP mice were intravenously injected with 5,000-10,000 MPPS along with 
3x105 helper bone marrow cells from a separate UBC-GFP mouse two days after mice were 
given two equal doses of 500 cGy lethal irradiation using a Cesium 137-based gamma-ray 
irradiator. UBC-GFP mice were used as recipients because of their ubiquitous GFP expression 
in all cell types, including erythrocytes and platelets. Donor cells were identified by their lack of 
GFP expression. Percentages of donor cells represent the proportion of GFP negative cells 




Analysis of HSPC progeny following myeloablation  
Following lethal irradiation as described above, individual CD45.1 recipients were intravenously 
injected with 2,500 LT-HSCs, 5,000 MPP2, or 5,000 MPP3 without competitive/helper cells. All 
donor cells were CD45.2+. Eighteen days post-transfer, bone marrow and spleen of recipient 
mice were analyzed for total chimerism, donor-derived MPPS and donor-derived LSKs. In 
separate experiments, UBC-GFP mice were injected with 50 GFP- LT-HSCs (Lin-
Sca1+cKit+CD150+CD48-) and 2x105 UBC-GFP+ whole bone marrow cells and analyzed 10 
weeks later for GFP- MPPS cells in spleens of recipient mice.  
    
Statistics  
Unpaired, student t-tests were performed to obtain p-values using Prism 6 (GraphPad) software. 
Welch’s correction was applied when the calculated F-test provided significantly different 





























3.4.1. The effect of NR4A1 on myeloid progenitor populations  
 
To explore the role of NR4A1 in myeloid progenitor cell differentiation, we compared 
Lineage-Sca1-cKit+ (L-S-K+) progenitor cell populations between Nr4a1-deficient (Nr4a1-/-) versus 
WT mice. We identified granulocyte-macrophage progenitors (GMPs) and megakaryocyte 
progenitors (MkPs) by their expression of CD16/32 and CD41, respectively, and used CD105 
and CD150 expression to distinguish early granulocyte-macrophage progenitors (Pre-GMs), 
megakaryocyte-erythroid progenitors (Pre-MegEs), and erythroid progenitors (Pre-CFU-Es and 
CFU-Es) (Figure 3.1) [260]. We found no significant differences in bone marrow progenitors 
between Nr4a1-/- and WT mice (Figure 3.3A). In contrast, we observed a 2-fold increase in the 
total cell number of CD150-CD105+ CFU-E progenitors in the spleens of Nr4a1-/- compared to 
WT mice (Figure 3.3A). Using another pair of surface markers, CD71 and CD24, which have 
also been shown to identify CFU-Es among L-S-K+CD16/32-CD41- cells [264], we observed the 
same 2-fold increase in CFU-E progenitors in the spleens of Nr4a1-/- mice and no differences in 
the bone marrow (Figure 3.3B).  
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Figure 3.3. Nr4a1-/- mice have increased erythroid progenitors in the spleen. 
(A) A comparison of myeloid progenitors between WT and Nr4a1-/- mice from the bone marrow 
and spleen with quantification of their total cell number. n=7. (B) The CD71/CD24 cell surface 
profile of splenic Lin-Sca1-cKit+CD16/32-CD41- cells from WT and Nr4a1-/- mice analyzed for 
CD71highCD24high CFU-Es in WT and Nr4a1-/- mice. n=5. *p<0.05. Error bars represent SEM.  
 
 
We confirmed these findings by evaluating the formation of CFU-E colonies in culture.  
Splenocytes from Nr4a1-/- mice plated onto methycellulose produced twice as many CFU-E 
colonies than WT splenocytes (Figure 3.4B). We saw no significant difference in the number of 
CFU-Es generated from Nr4a1-/- versus WT bone marrow cells (Figure 3.4A). These data 
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indicate that NR4A1 plays an unanticipated role in modulating erythropoiesis, specifically in the 
spleen.  
 
Figure 3.4. Functional, splenic CFU-Es are more represented in Nr4a1-/- spleens.   
(A, B) CFU-E colony formation of WT and Nr4a1-/- mice bone marrow cells and splenocytes. 
Roughly 200-1000 colonies were counted from each group from each independent experiment. 
n=2. Error bars represent SEM.	  	  	  
3.4.2 NR4A1 function during normal and stress erythropoiesis   
 
Since Nr4a1-/- CFU-Es are able to form colonies of differentiated erythroid cells in 
methylcellulose, the increase in splenic CFU-E in Nr4a1-/- mice does not appear to be caused by 
a block in the ability of CFU-Es to differentiate. To further evaluate this possibility, we examined 
later stages of erythropoiesis in Nr4a1-/- mice using flow cytometry. Among glycophorin A-
positive (Ter119) cells, we observed no differences in terminal erythropoiesis at any stage, as 
determined by CD44 expression, in both the spleen and bone marrow (Figure 3.5A) [265]. 
Moreover, we detected similar peripheral red blood cell counts between WT and Nr4a1-/- mice 
(Figure 3.5B), consistent with previous studies from Ramirez-Herrick et al [201]. Thus, NR4A1 
does not detectably influence the differentiation of CFU-E into erythroblasts and mature red 




Figure 3.5. Nr4a1-/- mice display normal red blood cell development beyond the CFU-E 
progenitor stage. (A) GlycophorinA (Ter119) positive whole bone marrow and splenocytes 
were stained for CD44 to identify pro-erythroblasts (I), basophilic erythroblasts (II), 
polychromatic erythroblasts (III), orthochromatic erythroblasts and reticulocytes (IV), and mature 
RBCs (V).[265] n=5. (B) Complete blood counts showing RBC counts and RBC volume by 
hematocrit. n=3. Error bars represent SEM.    
 
 
To determine whether the increase in splenic CFU-Es in Nr4a1-/- mice was due, instead, 
to effects on more immature cells capable of differentiating to CFU-Es, we first analyzed the 
number of “burst” erythroid progenitors, BFU-Es, in Nr4a1-/- mice under steady state and stress 
conditions. We found minimal baseline differences in BFU-Es, marked by L-S-K+CD16/32-CD41-
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CD71lowCD24low expression [264], in the bone marrow and spleens of WT and Nr4a1-/- mice 
(Figure 3.6A, B). Consistent with these data, WT and Nr4a1-/- splenocytes generated similar 
numbers of BFU-Es after 10 days in methylcellulose (Figure 3.6C).  
 
 
Figure 3.6. Nr4a1-/- mice have normal BFU-E numbers. (A) Cells that were L-S-K+CD16/32-
CD41- were analyzed for CD71 and CD24 expression to delineate BFU-Es [264]. (B) Total cell 
number of BFU-Es in the bone marrow and spleens of WT and Nr4a1-/- mice. n=5. (C) BFU-E 
colony assay of bone marrow and splenocytes from two independent experiments. Error bars 
represent SEM.    
  
Since the spleen is the primary site of glucocorticoid-induced BFU-E expansion and 
differentiation in response to blood loss [264, 266], we asked whether the differences in splenic 
CFU-E pools might be a reflection of stress erythropoiesis, i.e. NR4A1 might hinder the 
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response of stress erythropoiesis [267]. However, we found that Nr4a1-/- BFU-Es proliferated at 
a similar rate to WT BFU-Es in response to glucocorticoid stimulation with dexamethasone 
(Figure 3.7A). Similarly, Nr4a1-/- mice recovered from phenylhydrazine-induced hemolytic 
anemia in vivo at the same rate as did WT mice (Figure 3.7B). Taken together, our 
measurements of both BFU-E number and function indicate that neither steady state nor stress 
erythropoiesis within the BFU-E compartment relies on NR4A1, thus raising the possibility that 
NR4A1 might act on a different progenitor cell type which can produce CFU-E. 
 
Figure 3.7. Nr4a1-/- mice respond normally to stress erythropoiesis. (A) Splenic BFU-Es 
from WT and Nr4a1-/- mice were sorted and placed into liquid culture with or without 100nM 
dexamethasone. Data represents two individual experiments. (B) Mice were injected with 
60mg/kg phenylhydrazine (PHZ) at day 0 and day 1. Complete blood counts of peripheral blood 





3.4.3. Regulation of NR4A1 expression in erythroid progenitors    
 
To identify a candidate precursor population that might be sensitive to the loss of NR4A1 
expression, we took advantage of the NR4A1GFP reporter mouse. Specifically, we examined 
NR4A1 expression among L-S-K+CD41-CD16/32- cells with erythroid potential, using CD71 and 
CD24 expression to differentiate between BFU-E and CFU-E populations [264]. Consistent with 
our findings that BFU-E and CFU-E functioned normally in Nr4a1-/- mice, very few cells within 
the BFU-E and CFU-E sub-populations expressed NR4A1 (Figure 3.8A). Instead, the majority of 
cells that expressed NR4A1GFP fell within a distinct, previously uncharacterized sub-population 
marked by low expression of CD71 and high expression of CD24 (CD71lowCD24high). Gating 
directly on the L-S-K+CD41-CD16/32-CD71lowCD24high population, we found that ~19% of these 
cells express very high levels of NR4A1 in the spleen, compared to only 4.6% in the bone 
marrow (Figure 3.8B). Neither BFU-E nor CFU-E sub-populations expressed NR4A1GFP (Figure 
3.8B). These data indicate that the L-S-K+CD41-CD16/32-CD71lowCD24high cells are a distinct 
population in the spleen, where they include a significantly higher percentage of NR4A1+ cells 





Figure 3.8. NR4A1 expression identifies a previously uncharacterized splenic progenitor 
population. (A) Spleen cells (Lin-Sca1-cKit+CD41-CD16/32-) were gated for GFP expression 
and profiled for CD71 and CD24 identifying a distinct CD71lowCD24high population. (B) Bone 
marrow and splenic L-S-K+CD16/32-CD41- cells were gated for CFU-E, BFU-E and 
CD71lowCD24high populations and examined for NR4A1 GFP expression. Data is representative 
of 3 independent experiments.  
  
     
Although only a fraction of the L-S-K+CD71lowCD24high population in the spleen and bone 
marrow expressed high levels of NR4A1, all cells in this population were capable of responding 
to signals that induce NR4A1 expression. Both splenic and bone marrow cKit+CD71lowCD24high 
cells up-regulated NR4A1 within 1 hour after in vitro stimulation by PGE2, but not SCF, G-CSF, 
or LPS (Figure 3.9A,B). These observations suggest that the fate of this population can be 





Figure 3.9. Splenic L-S-K+CD71lowCD24high cells respond robustly to PGE2 treatment. 
NR4A1 induction in L-S-K+CD16/32-CD41-CD71lowCD24high cells from the bone marrow (A) and 
spleen (B) in response to 1 hour in vitro stimulation with various factors including PGE2. n=2. 
*p<0.05. **p<0.01. Error bars represent SEM.  
 
 
3.4.4 Characterization of splenic CD71lowCD24high cells   
 
To understand how this unique population is regulated, we first compared their 
frequencies in the bone marrow and spleen along with other known progenitor populations. We 
observed several subtle differences among previously identified progenitor subsets, all of which 
were less represented in the spleen compared to the bone marrow (Figure 3.10A). Within the L-
S-K+ population, CD41+ lineage-restricted MkPs were present in similar proportions in both 
organs and GMPs were represented at significantly lower frequencies in the spleen (Figure 
3.10B). Splenic CD71lowCD24high cells within the L-S-K+ progenitor pool were 10-times more 
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represented compared to the bone marrow (Figure 3.10B). Interestingly, NR4A1 expression did 
not affect the generation of L-S-K+CD71lowCD24high cells per se; they were present in similar 
numbers in WT and Nr4a1-/- mice (Figure 3.10C).    
 
Figure 3.10. Phenotypic characterization of bone 
marrow and splenic hematopoietic stem and progenitor 
cells. (A) Gating scheme used to identify Lineage negative 
(Mac1, Gr1, Ter119, CD3, B220, Nk1.1) populations in the 
bone marrow and spleen. (B) A comparison of bone 
marrow and splenic L-S-K+ populations including MkPs, 
GMPs, and CD71lowCD24high cells. Numeric values 
represent the proportion of each cell population among the 
L-S-K+ progenitor pool. Each dot represents an individual 
mouse. n= at least 4 per group. **p<0.01. ****p<0.0001. (C) 
L-S-K+CD16/32-CD41-CD71lowCD24high populations in WT 
and Nr4a1-/- mice. n=5. Error bars represent SEM.      	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To measure the developmental potential of this cell subset, we first cultured sorted 
splenic L-S-K+CD41-CD16/32-CD71lowCD24high cells in methylcellulose in the presence of 
multiple hematopoietic growth factors. These cells generated monocyte and granulocyte 
colonies (CFU-GM, G and M), erythroid colonies (BFU-E) and megakaryocyte colonies (CFU-
Mk) demonstrating their clonogenic capacity and multipotent myeloid potential (Figure 3.11A). 
Flow cytometric analysis of pooled methylcellulose colonies confirmed the presence of cells 
expressing lineage-restricted markers Mac1, Gr1, Ter119 and CD41 (Figure 3.11B). We 
therefore designate the novel L-S-K+CD41-CD16/32-CD71lowCD24high population “multipotent 




Figure 3.11. Splenic CD71lowCD24high cells have multi-lineage potential in vitro. (A) Sorted 
splenic L-S-K+CD41-CD16/32-CD71lowCD24high cells were plated onto methylcellulose medium 
and characterized by their appearance. Bar graphs represent an average of three individual 
wells from two independent experiments. (B) Colonies from individual wells were pooled and 
stained with antibodies against Ter119, CD41, Mac1 and Gr1. Error bars represent SEM.     
  
 
To assess the differentiation potential of MPPS in vivo, we adoptively transferred 1x104 
WT (non-fluorescent) sorted MPPS along with 3x105 GFP+ helper bone marrow cells into 
lethally irradiated UBC-GFP mice (Figure 3.12A). Twelve days later, GFP- donor cells were 
detected in the blood, bone marrow, and spleens of recipient mice, but not in their thymus or 
lymph nodes (Figure 3.12B,C). Donor-derived (GFP-) cells contributed to erythroid populations, 
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comprising 2-5% of total Ter119+ cells in the peripheral blood, bone marrow, and spleen. Donor 
platelets were also present in the peripheral blood and spleen, but not in the bone marrow. 
MPPS-donor derived cells contributed to neutrophil and monocyte populations, including 
Ly6Chigh monocytes, in the spleen but not in the bone marrow (Figure 3.12C).  
Since lymphocytes are often the last lineage to re-populate from HSCs after lethal 
irradiation [175, 183, 268], we also looked for the presence of all lineages, including 
lymphocytes, 4 weeks post-transplant. No lymphocytes were detected, and at that point we only 
found donor-derived erythrocytes in the bone marrow, spleen and peripheral blood, consistent 
with their 40-day half-life (Figure 3.12C). Thus, while MPPS do not develop into lymphoid cells, 
they have the potential to differentiate in vivo into several different myeloid lineage subsets 
including red blood cells, platelets, monocytes, and neutrophils, most notably within the spleen. 
Of note, we also did not detect any donor-derived MPPS in any organ at four weeks, suggesting 
this population has limited self-renewal capacity (Figure 3.12D). 
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Figure 3.12. MPPS demonstrate 
megakaryocyte, erythrocyte, and 
monocyte/granulocyte potential in vivo. (A) 
Ten thousand sorted, splenic MPPS and 3x105 
GFP+ whole bone marrow (WBM) cells were 
injected into lethally irradiated UBC-GFP mice.  
 	  
thymus. MPPS-derived Mac1+ cells (that stained negative for CD3, CD4, CD8, CD19, and 
Ly6G) were gated for CD115 and Ly6C indicating the presence of Ly6Chigh classical 
monocytes within the donor-derived population. (D) Four weeks after transplanting GFP- 
MPPS into GFP+ recipients, MPPS cells analyzed for the presence of GFP expression were 
almost completely GFP+, indicating limited MPPS self-renewal capacity. Data represent mice 
from two independent experiments. n.d. none detected. Error bars represent SEM. 	  
(B) Twelve days later, recipient mice were gated for discrete 
lineage markers and analyzed for the absence of GFP expression. 
To control for the possibility that some GFP+ cells could lose GFP 
expression and confound the ability to distinguish donor (GFP-) 
from recipient and helper (GFP+) cells, some UBC-GFP recipients 
received GFP+ helper bone marrow cells only. Only trace amounts 
(<0.01%) of GFP- cells were observed in these control recipients. 
(C) Percentage of all donor-derived lineage positive cell types in 
the peripheral blood, bone marrow, spleen, lymph nodes and  	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To determine whether the expression of NR4A1 identifies distinct functional subsets in 
vitro, we purified and cultured NR4A1GFP+ and NR4A1GFP- MPPS from the bone marrow and 
spleen in methylcellulose. After 12 days, splenic NR4A1GFP+ cells produced larger colonies 
compared to NR4A1GFP- cells (Figure 3.13A) suggesting that NR4A1-expressing cells have a 
higher proliferative capacity. Consistent with the previous findings that NR4A1 expression limits 
erythroid potential, splenic NR4A1GFP+ cells generated significantly fewer BFU-E colonies 
(Figure 3.13B). Colonies from splenic NR4A1GFP+ cells were mostly monocytic and granulocytic 
in appearance (CFU-GM, CFU-G, and CFU-M) whereas NR4A1GFP- cells produced significantly 
fewer granulocyte/monocyte colonies. NR4A1GFP+ cells from the spleen also generated 
significantly fewer megakaryocyte colonies (CFU-Mk). These data indicate that MPPS, at the 




Figure 3.13. NR4A1 identifies a subset of progenitors with limited erythroid and 
megakaryocyte potential. Bone marrow and splenic NR4A1GFP+ and NR4A1GFP- cells within the 
MPPS population were plated onto methylcellulouse for 10-12 days. (A) Tile scans showing 
representative images of each cell population plated in triplicate from separate experiments. 
Colony sizes from each tile scan image were measured and quantified. (B) Individual colonies 
from each well were characterized and quantified. Bar graphs represent colonies from individual 
wells averaged from three independent experiments. *p<0.05. **p<0.01. ***p<0.001. Error bars 
represent SEM.                     
 
 
To directly measure the potential of individual cells within the MPPS population, we 
sorted single NR4A1GFP+ or NR4A1GFP- MPPS cells into 96-well plates, cultured them in the 
presence of known hematopoietic growth factors, and examined their appearance and 
phenotype (Figure 3.14A-C). About 35% of colonies derived from single, NR4A1GFP+ cells were 
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multipotent and generated cells that stained positive for CD41, Ter119, and Mac1 or Gr1 (Figure 
3.14A). Conversely, colonies derived from single NR4A1GFP- cells were mostly unipotent, 
contained very few Mac1+ or Gr1+ cells (Figure 3.14A, B), and all stained positive for CD41 or 
Ter119 (Figure 3.14C). Single NR4A1GFP+ cells generated significantly fewer colonies that were 
Ter119+ or CD41+, whereas ~85% of these colonies were Mac1+ or Gr1+, consistent with the 
data from Figure 3.13B. Thus, NR4A1 expression specifically identifies multipotent MPPS cells 
that are biased toward monocyte and granulocyte development. Moreover, these observations 
raise the possibility that NR4A1 plays a role in restricting the ability of MPPS to differentiate 
towards erythroid/megakaryocyte lineages. 
 
Figure 3.14. Single cell analysis revealed NR4A1 expression identifies a multipotent 
population within MPPS. Myeloid differentiation potential of single NR4A1GFP+ and NR4A1GFP- 
MPPS from was determined by performing flow cytometry on individual colonies for Ter119, 
CD41, Mac1 and Gr1 expression. (A) Colonies were scored as multipotent if Ter119+, CD41+ 
and Mac1+ and/or Gr1+ cells were distinguishable in separate populations. (B) The proportion 
of colonies that contained Mac1+ or Gr1+ cells. (C) The proportion of colonies that were 
Ter119+ or CD41+. A single colony can include both Mac1+/Gr1+ and Ter119+/CD41+ cells 
and are therefore scored as both. These data represent two individual experiments in which ~25 
colonies were analyzed per group in each experiment.   
 
3.4.5. Function of NR4A1 in multipotent progenitors of the spleen 
 
To directly assess the function of NR4A1 within the MPPS population in vivo, we 
compared the lineage potential of MPPS from Nr4a1-/- and WT mice by injecting 5x103 splenic 
MPPS into lethally irradiated UBC-GFP recipients. Notably, Nr4a1-/- splenic MPPS generated 
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five to ten-fold more Ter119+ erythrocytes in the peripheral blood than WT MPPS (Figure 3.15 
A,B), indicating that NR4A1 acts in this specific population to restrict their erythroid potential. 
Nine days after the cells were injected, 10% of total erythrocytes in the peripheral blood were 
derived from Nr4a1-/- MPPS whereas only ~1% of erythrocytes were generated from WT MPPS. 
By day 12, >5% of erythrocytes were derived from Nr4a1-/- MPPS donor splenocytes versus 
~1% from WT MPPS. MPPS-derived platelet populations were also affected by NR4A1 
expression. At day 12, Nr4a1-/- MPPS contributed 1.7% of the total CD41+ platelet population in 
the peripheral blood compared to 0.4% from WT MPPS (Figure 3.15B). These data indicate that 
NR4A1 activity in MPPS limits their erythroid and megakaryocyte differentiation potential, and 
suggests a new role for NR4A1 in myeloid progenitor cell development. 
 
 
Figure 3.15. NR4A1 limits platelet and erythroid differentiation of MPPS in vivo. Five 
thousand MPPS from WT and Nr4a1-/- mice were injected with 3x105 GFP+ whole bone marrow 
into UBC-GFP recipients. Cells that were Ter119+ were analyzed for GFP expression. (A) 
Donor erythrocytes present in the peripheral blood at days 6, 9, and 12 averaged from two 
independent experiments. In the right panels, each dot represents an individual mouse at the 
times indicated. (B) Donor platelets in the peripheral blood. *p<0.05. **p<0.01. Error bars 
represent SEM.   
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3.4.6. NR4A1 regulation of hematopoietic stem and progenitor cells  
 
Since the splenic niche regulates MPPS through NR4A1 and myeloid-biased LT-HSCs 
in the bone marrow are identified by NR4A1 expression [187], we set out to test whether the 
hematopoietic stem cell compartment in the spleen was also sensitive to NR4A1. To further 
understand the spatial regulation of NR4A1, we examined all hematopoietic stem and progenitor 
cell sub-populations (HSPCs), including LT-HSCs, for NR4A1 expression in the bone marrow 
and spleen using NR4A1GFP mice (Figure 3.16A, B). Within the LSK compartment, we identified 
CD48-CD150+ LT-HSCs and CD48-CD150+ ST-HSCs that were both FLT3- (Figure 1.7). Both 
CD150+CD48+ MPP2 and CD150-CD48+ MPP3 populations at steady state exhibit an 
erythrocyte/megakaryocyte and a granulocyte/monocyte bias, respectively, were also negative 
for FLT3 expression. Lymphoid-biased MPP4 were FLT3+. Consistent with our previously 
published data, only a small proportion of bone marrow LT-HSCs expressed high levels of 
NR4A1 in the bone marrow (Figure 3.16B). Conversely, with the exception of MPP2, all splenic 
LSK populations expressed NR4A1 to varying degrees. Splenic LT-HSCs expressed the highest 
levels of NR4A1, followed by MPP4, ST-HSCs, and finally MPP3 (Figure 3.16C). These data 




Figure 3.16. Multiple HSPC sub-types express NR4A1 in the spleen. (A) Bone marrow and 
splenic LSKs sub-populations were analyzed for NR4A1GFP expression and quantified (B) using 
median fluorescence intensity (MFI) relative to non-transgenic, WT littermante controls (LMC). 
For bone marrow populations, these data represent two mice that were analyzed individually. 
For splenic populations, splenocytes from 2 mice were pooled and analyzed by flow cytometry. 
Error bars represent SEM. 
 
     
A variety of cell types in the spleen express NR4A1, including MPPS and LT-HSCs, 
however, these data do not demonstrate whether NR4A1 functions within the HSPC 
compartment. To determine if NR4A1 also affects erythrocyte development of LT-HSCs, we 
injected 50 GFP- LT-HSCs isolated from WT and Nr4a1-/- mice into lethally irradiated UBC-GFP 
recipients along with GFP+ whole bone marrow cells. After 12 days, Nr4a1-/- LT-HSCs 
generated almost 5-times more erythrocytes compared with WT LT-HSCs in the peripheral 
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blood (Figure 3.17A). These data mirror the results from Figure 13A, in which Nr4a1-/- MPPS 
produce 5-10 fold more peripheral blood erythrocytes. However, 3 weeks post-transplantation, 
we detected similar levels of donor-derived erythrocytes in the peripheral blood from WT and 
Nr4a1-/- LT-HSCs (Figure 3.17B). Thus, NR4A1 limits erythropoiesis during the early phase of 
regeneration following myeloablation. Given that all hematopoietic cells including MPPS develop 
from LT-HSCs, these data might merely reflect LT-HSCs passing through the MPPS stage.  
 
Figure 3.17. NR4A1 in LT-HSCs limits their erythroid potential in the immediate recovery 
phase following myeloablation.  Fifty, GFP- bone marrow LT-HSCs from WT and Nr4a1-/- 
mice were purified and intravenously injected along with GFP+ helper whole bone marrow cells 
into lethally irradiated UBC-GFP recipient mice. Peripheral blood analysis for the appearance of 
donor-derived (GFP-) erythrocytes was performed 12 days (A) and 3 weeks (B) post-injection.        
 
3.4.7. Multipotent progenitors of the spleen ontogeny: identification of an upstream 
progenitor cell  
 
To understand if MPPS develop directly from the LT-HSC or from a more restricted 
progenitor within the LSK compartment, we examined the potential of LT-HSCs and other MPP 
populations to develop into MPPS. We included both MPP2 and MPP3 sub-populations due to 
their capability to differentiate into myeloid cell types, especially during regenerative conditions 
[172, 183]. We purified and injected 2,500-5,000 CD45.2+ MPP2, MPP3, or LT-HSCs into 
lethally irradiated congenic recipients (CD45.1+). Eighteen days later, donor-derived MPPS 
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were detectable in the spleens in all recipient mice that received LT-HSCs, with as many as 
90% of splenic MPPS being LT-HSC-derived (Figure 3.18A, B). Similarly, in mice that received 
MPP2, ~70% of MPPS were donor-derived. In contrast, transplanted MPP3 contributed less 
than 2% of MPPS. Together, these data suggest that MPP2 and LT-HSCs, not MPP3, which 
have previously been described as granulocyte/macrophage biased [183], generate MPPS in 
the recovery phase after myeloablation. LT-HSCs continue to give rise to donor-derived MPPS, 
even ten weeks after transplantation, indicating that MPPS continue to develop from stem cells 
beyond the immediate recovery phase (Figure 3.18C). 
 
Figure 3.18. MPPS develop from LT-HSCs and MPP2, not MPP3. (A, B) Sorted HSPC 
populations (CD45.2), isolated from the bone marrow, were injected into lethally irradiated 
recipients (CD45.1). Eighteen days later, MPPS populations in the spleen were analyzed for 
their donor and recipient components. Data are representative of at least two individual mice. 
Error bars represent SEM. (C) In a separate experiment, 50 LT-HSCs (GFP-) were injected into 
lethally irradiated recipients (GFP+) along with GFP+ competitor cells and analyzed for MPPS 
populations in recipient spleens. GFP- cells represent contribution of donor LT-HSCs to the 
MPPS population.  
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Interestingly in the bone marrow, very few MPPS developed from MPP2, which might 
simply reflect the nature of MPPS to localize to the spleen (Figure 3.19). Although MPPS are 
rare in the bone marrow, we were able to detect LT-HSC-derived MPPS there (Figure 3.19A, B). 
These data illustrate the ability of MPPS to circulate between the bone marrow and spleen or 
suggest LT-HSCs differentiate into MPPS in different physical locations. However, since MPP2 
generate MPPS in the spleen and not the bone marrow, it is possible that these particular HSPC 




Figure 3.19. Only LT-HSCs produced 
MPPS that were localized to the 
bone marrow.   (A) Donor and 
recipient contribution to MPPS found in 
the bone marrow 18 days after mice 
received LT-HSC, MPP2, or MPP3. (B) 
Quantification of chimerism represents 
at least 2 mice from each group. Error 
bars represent SEM.     	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3.4.8. Hematopoietic stem and progenitor cell function in the spleen in response to 
myeloablation 
 
To determine the ability of HSPCs to undergo differentiation in different physiological 
locations, we examined the total cell chimerism, including both mature and immature cells, in 
the bone marrow and spleens in mice that received MPP2, MPP3, or LT-HSCs. In mice that 
received LT-HSCs, almost 80% of all bone marrow cells and 60% of splenocytes were donor-
derived whereas MPP3 progeny was barely detectable in either compartment (Figure 3.20A, B). 
Conversely, MPP2 contributed to ~45% of all cells in the spleen and only 25% of the bone 
marrow cell population. These data suggest MPP2, but not LT-HSCs, preferentially differentiate 
in the spleen.  
 
Figure 3.20. MPP2 progeny are more represented in the spleen. Recipient mice were 
analyzed for LT-HSC, MPP2, or MPP3 contribution to the total number of cells in the bone 
marrow (A) and spleen (B). Data represents chimerism from at least 2 recipient mice from each 
group. Error bars indicate SEM.     
 
If MPP2 preferentially localize to the spleen and there differentiate, then we might expect 
to find undifferentiated MPP2 in the spleen at the same time point. To test the ability of MPP2 to 
be maintained in the spleen 18 days post-transplant, we compared the proportion of MPP2-
derived LSKs in the spleen to the bone marrow (Figure 3.20A, B). These analyses do not 
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distinguish different LSK sub-populations. However, it was suggested that MPP2 do not de-
differentiate into LT-HSCs or ST-HSCs nor do they generate MPP3 or MPP4 [183]. Therefore, 
the presence of MPP2-derived LSKs in the spleen might indicate their ability to self-renew there. 
Indeed, we discovered 20% of LSKs present in the spleen developed from MPP2. The bone 
marrow contained less than 1% of MPP2-derived LSKs. Thus, not only do MPP2 appear to 
preferentially differentiate in the spleen, but they also maintain the ability to self-renew in the 
spleen for at least 3 weeks. Transplanted LT-HSCs generated similar proportions of LSKs in the 
bone marrow and in the spleen (~50%). Not surprisingly, LSKs from MPP3 were undetectable at 
this time point. Together, these data suggest that HSPC sub-types maintain different self-
renewal and differentiation kinetics, which is location dependent.   
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Figure 3.21. MPP2 self-renew in the spleen, but not in the bone marrow. Representative 
flow cytograms of bone marrow (A) and splenic (C) LSKs in mice that received LT-HSCs, 
MPP2, or MPP3. Proportion of donor and recipient LSKs in the bone marrow (B) and spleen (C). 
Data represent at least two individual recipients. Error bars indicate SEM.    
   
The environment cultivated by the spleen is important for amplification and differentiation 
of HSPCs, especially in response to stress. For certain populations of multi-lineage progenitor 
cells, NR4A1 expression regulates their erythrocyte/megakaryocyte (Ery/Mk) to 
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granulocyte/monocyte (G/M) output (Figure 3.22). In the presence of NR4A1, HSPC 
differentiation generates a more balanced ratio of Ery/Mk to G/M cells. Without NR4A1, the ratio 
of Ery/Mk to G/M cells is skewed in favor of the production of erythrocytes and platelets. This 
effector function of NR4A1 in myeloid lineage commitment, which is particularly significant in the 
spleen, indicates signals of the local environment influence myeloid progenitor differentiation 





Figure 3.22. NR4A1 affects HSPC differentiation in the spleen. A model of the hematopoietic 
stem cell differentiation hierarchy in the presence and absence of NR4A1 expression illustrating 
MPPS develop from MPP2. NR4A1 expression, within both MPPS and LT-HSCs, limits 
erythrocyte and platelet production. In the absence of NR4A1, HSPCs are no longer 
developmentally constrained resulting in the over-production of erythroid cells and platelets. 














3.5. Discussion  
 
 
In this study we identify a novel population of hematopoietic progenitors that are 
enriched in the spleen. We designate these MPPS and show that a proportion express high 
levels of NR4A1. MPPS have multi-lineage potential and contribute to erythroid, megakaryocyte, 
granulocyte and monocyte lineages. Most importantly, we show that NR4A1 expression 
influences the choice MPPS make to adopt these fates. Specifically, NR4A1 inhibits MPPS 
development to erythroid and megakaryocyte lineages. 
Although the role of the bone marrow in adult hematopoiesis is well described, the 
contribution of the spleen is less well understood. Our study adds several pieces of evidence 
indicating that the spleen makes a distinct contribution to hematopoiesis, particularly to myeloid 
development. Compared to the bone marrow, the spleen harbors a noticeably higher proportion 
of MPPS that are capable of generating Ly6Chigh monocytes (Figure 3.10B and Figure 3.12C). 
Even though the spleen is predominantly comprised of red blood cells and lymphocytes, the 
spleen also maintains a population of both Ly6Chigh and Ly6Clow monocytes that have been 
shown to play a role in atherosclerosis, myocardial infarction, cancer, and acute infection [256, 
258, 259, 269]. These splenic reservoir monocytes (SRM) are thought to originate from bone 
marrow GMPs that mobilize to the spleen [258]; however, splenic GMPs are maintained at 
much lower frequencies in the spleen versus the bone marrow (Figure 3.10B). Since GMPs are 
not well represented within the splenic progenitor pool, MPPS serve as an attractive alternative, 
or at the very least, additional local source of SRM.  
To determine the functional relevance of MPPS, future studies might include an 
investigation of MPPS in models where SRM function to resolve particular disease states and 
require replenishment. An examination of how the MPPS population changes, expanding or 
diminishing in response to LPS-treatment for example, might be a first indication that MPPS 
play a role in resolving acute infection. MPPS differentiation into SRM in response to LPS 
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infection would indicate MPPS are, indeed, an SRM progenitor. This could be achieved through 
pulse-chase experiments where GFP+ MPPS are injected into GFP- recipients followed 
immediately by LPS stimulation. The appearance of GFP+ SRM cells would indicate MPPS 
develop into SRM in response to LPS treatment. MPPS may therefore play a physiological role 
during the early stages of infection or other inflammatory stresses.  
Differentiation of MPPS in response to infection might involve or be controlled by 
NR4A1. Our initial studies suggest that a short stimulation with LPS does not directly induce 
NR4A1 expression (Figure 3.9B). However, MPPS rapidly up-regulate NR4A1 in response to 
PGE2 (Figure 3.9B), a locally active lipid compound that elicits both inflammatory and 
immunosuppressive responses. PGE2 rapidly induces NR4A1 expression in a variety of cell 
types, including LT-HSCs [186, 187, 270-272]. PGE2 promotes granulopoiesis in response to 
bacterial infection and HSC proliferation and engraftment after bone marrow transplant, perhaps 
through its activation of NR4A1 [168, 170, 273]. Taken together, these observations raise the 
possibility that during the acute inflammatory phase, PGE2’s rapid and robust activation of 
NR4A1 in MPPS could drive them away from erythro-megakaryocyte differentiation, toward 
granulocyte and monocyte development. This could be tested by stimulating WT and Nr4a1-/- 
MPPS with PGE2 and assessing their progeny in vitro and in vivo. The unique ability of the 
spleen to stimulate robust NR4A1 expression also may explain why we observe monocytes in 
the spleen but not the bone marrow after adoptive transfer of MPPS. Our observations suggest 
that the spleen is uniquely poised to contribute to myelopoiesis and may be an important source 
of monocytes.   
The discovery of a new, independent role for NR4A1 in myeloid cell development was 
unexpected since NR4A family members often share redundant functions. Mice deficient for 
both NR4A1 and NR4A3 die from acute myeloid leukemia (AML) shortly after birth and leukemic 
blasts from patients with AML have reduced levels of both NR4A1 and NR4A3 albeit through 
unknown mechanisms [200]. Since AML results from immature myeloid progenitors that fail to 
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differentiate, these studies implicate the NR4A family as a critical regulator of myeloid progenitor 
differentiation. NR4A1 deficiency alone is not sufficient to induce AML or myelodysplasia [201], 
but NR4A1 is required for the development of non-inflammatory, patrolling monocytes [245]. Our 
laboratory previously demonstrated that NR4A1 expression identifies myeloid-biased LT-HSCs 
[187], but whether NR4A1 by itself functions to regulate cell fate within the myeloid progenitor 
compartment was previously unknown. Our present data demonstrate that NR4A1 plays a 
distinct, non-redundant role in myeloid progenitor development, restricting erythropoiesis and 
megakaryopoiesis within the MPPS population. Differences between the transcriptional 
signatures, focusing on known regulators of myeloid differentiation like PU.1 and GATA1, in WT 
and Nr4a1-/- MPPS might help determine the mechanism by which NR4A1 controls cell fate 
within the MPPS population.  
The multipotent nature of MPPS highlights the developmental plasticity that has also 
been attributed to other multipotent progenitors, which are believed to alter their developmental 
pathway depending on their environmental context [183]. Under homeostatic conditions, 
different subsets of MPPs show lineage bias towards megakaryocytes and erythrocytes, 
monocytes and granulocytes, or lymphocytes. However, in the early stages of regeneration 
following myeloablation, lymphoid-biased MPP activate a myeloid transcriptional program and 
therefore presumably contribute to the myeloid compartment. This indicates that their lineage 
commitment is not fixed, but instead influenced by extrinsic regulatory factors. Similarly, we 
show that activation of NR4A1 in MPPS, which limits their erythroid and megakaryocyte 
potential, is higher in the spleen than the bone marrow, thereby suggesting niche-specific 
influences on MPPS cell fate. Thus, for certain populations of hematopoietic progenitors, 
lineage choice is neither fixed nor completely stochastic, but rather mediated by external cues.  
The spleen provides a nurturing environment for MPPS and HSPCs in the regeneration 
phase following myeloablation. Eighteen days after transplant, LT-HSCs and MPP2 develop into 
MPPS specifically in the spleen. Interestingly, MPP2 progeny include an LSK population in the 
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spleen, but not in the bone marrow. Assuming these LSKs derived from proliferating MPP2, our 
data suggest MPP2 are indeed capable of self-renewal and undergo expansion specifically in 
the spleen. These data challenge previous published work that suggest MPP populations do not 
self-renew, although these reports only examined the bone marrow populations [183]. 
Furthermore, the self-renewal activity specific to MPP2, and not MPP3, illustrates differences in 
the capabilities of MPP sub-types, which might explain why, compared to MPP3 and MPP4, the 
molecular signature of MPP2 is most similar to the self-renewing LT-HSCs and ST-HSCs [183]. 
Future experiments might include confirmation that the donor-derived LSK population displays 
the FLT3-CD150+CD48+ MPP2 phenotype. If MPP2-derived LSK populations include cells with 
the MPP3 or MPP4 phenotype, these results would indicate that MPP2 sit higher up on the 
hematopoietic hierarchy than originally described and produce MPP3 and MPP4 [182, 183]. 
Furthermore, any underlying differences in the transcriptome between the rapidly expanding 
MPP2 in regenerative conditions compared to MPP2 in the steady state spleen and bone 
marrow could help identify influential signals in the splenic niche that simulate their self-renewal.    
Our study suggests the spleen provides a unique contribution to steady state and 
regenerative hematopoiesis. Further dissection of the regulatory factors and niche components 
will provide insight into the myeloid-biasing nature of the spleen that often occurs under stress. 
This is not only important for understanding extramedullary hematopoiesis critical for responding 
to hematopoietic challenges, but may also uncover basic mechanisms of myelopoiesis that can 
be exploited or hijacked by blood cancers. 













These two distinct, independent studies highlight a unifying feature of all stem cells: 
stem cells are intrinsically controlled yet externally regulated. Pluripotent stem cells (PSCs) and 
hematopoietic stem cells (HSCs) require transcriptional networks to maintain their potential and 
to induce their differentiation. Environmental signals provide precise instructions that mediate 
their cell fate.  
Through our studies of mitochondrial shapes in human PSCs and their derivatives, we 
discovered that mitochondria maintained their long, filamentous, and networked phenotype in 
stem cell renewing conditions even throughout all stages of mitosis, an unpublished observation 
in mammalian cells. In response to definitive endoderm (DE) induction, mitochondria underwent 
acute fragmentation and became short, punctate and globular, prior to the initiation of the DE-
specific transcriptional program. The observed fragmentation did not occur in hPSC 
differentiation to mesoderm (MD) or neuroectoderm (NE) suggesting that this type of 
mitochondrial shape change was induced in a germ layer-specific manner. At the very least, the 
difference in mitochondrial shape reflects two distinct cell states, defined by different 
transcriptional programs and mediated by external signaling factors. Whether these 
mitochondrial morphologies help regulate stem cell maintenance and differentiation from within 
is important for understanding their impact on cell fate in early human development.    
In Chapter 3, we discovered that the spleen provides a distinct environment that affects 
hematopoietic stem and progenitor cell (HSPC) fate. The activation of NR4A1 expression in 
multipotent progenitors of the spleen (MPPS) directed their differentiation away from 
erythrocyte/megakaryocyte lineages, towards monocyte/granulocyte cells. Several HSPC sub-
types expressed NR4A1 in the spleen, but not in the bone marrow suggesting that the spleen 
cultivates an environment that controls myeloid differentiation programs. During regeneration of 
the entire hematopoietic system, the spleen fostered the proliferation and differentiation of 
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MPP2, not MPP3, two myeloid-biased multipotent progenitor populations. Importantly, the bone 
marrow did not support MPP2, however, it provided a niche for LT-HSCs to expand and 
differentiate. These niche capabilities that differed between the bone marrow and spleen 
suggests that under regenerative conditions, the environment regulates HSPCs. Future studies 
into the components of the splenic environment that direct HSPCs through NR4A1 during the 
steady state and by expansion during regeneration will provide new mechanistic insights into 
HSPC cell fate.   
The data presented here broadly impact stem cell research. These two studies confirm 
the idea that cells with differentiation potential are defined by interacting processes with varying 
degrees of control. In addition, they extend the knowledge of mitochondria in differentiating 
hESCs and illuminate the spleen’s contribution to hematopoiesis. These studies will help inform 
future hESC differentiation protocols and demonstrate the significance of the spleen in 
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